Descriptor: "MESH: Epidemiologic Methods" / Publication Year Range: Last 50 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"MESH: Epidemiologic Methods"' showing total 80 results

Start Over Descriptor "MESH: Epidemiologic Methods" Publication Year Range Last 50 years

80 results on '"MESH: Epidemiologic Methods"'

1. Seroepidemiology of Human Enterovirus 71 Infection among Children, Cambodia

Author: Alessio Andronico, Philippe Buchy, Channa Mey, Simon Cauchemez, Arnaud Tarantola, Henrik Salje, Philippe Dussart, Veasna Duong, Paul F. Horwood, Sovann Ly, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Modélisation mathématique des maladies infectieuses, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Johns Hopkins Bloomberg School of Public Health [Baltimore], Johns Hopkins University (JHU), Ministry of Health [Phnom Penh], GlaxoSmithKline Vaccines [Singapore], GlaxoSmithKline [Headquarters, London, UK] (GSK), This study was supported by the Second Health Sector Support Program, Ministry of Health of the Kingdom of Cambodia, and the Asian Development Bank., Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Salje, Henrik [0000-0003-3626-4254], and Apollo - University of Cambridge Repository
Subjects: 0301 basic medicine, Male, Epidemiology, encephalitis, lcsh:Medicine, medicine.disease_cause, MESH: Epidemiologic Methods, MESH: Estrogens, Disease Outbreaks, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Seroepidemiologic Studies, Enterovirus 71, Child, MESH: Estrone, biology, seroprevalence, enterovirus, EV71, Dispatch, virus diseases, MESH: Climate, MESH: China, 3. Good health, Infectious Diseases, MESH: Hawaii, Child, Preschool, MESH: Boston, Female, MESH: Estradiol, MESH: Culture, Cambodia, Encephalitis, Microbiology (medical), Adolescent, Virus, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, children, medicine, Enterovirus Infections, Seroprevalence, Humans, viruses, lcsh:RC109-216, MESH: Ovulation, MESH: Adolescent, MESH: Humans, business.industry, lcsh:R, Outbreak, MESH: Adult, biology.organism_classification, medicine.disease, Seroepidemiology of Human Enterovirus 71 Infection among Children, Cambodia, Virology, Enterovirus A, Human, Human enterovirus, 030104 developmental biology, Enterovirus, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, MESH: Breast Neoplasms
Abstract: International audience; In a 10-year incidence survey of breast cancer in the City of Boston, 14 cases in American Chinese women were observed, while approximately 13 were expected on the basis of age-specific incidence in the white population. In Hawaii, on the other hand, while breast cancer incidence rates for ethnic Chinese are approximately three times as high as those of indigenous Chinese populations, data indicate that they are still 35% lower than those of whites in Hawaii or on the US mainland. We have compared estrogen concentrations in the urine of Chinese women in the Orient, Honolulu, and Boston. Levels of estrone (E1) and estradiol (E2) increased greatly from the low to the high risk group. The increase was evident among both the younger (15-19 years) and the older (20-24 years) women, in both follicular and luteal phase specimens. The crude unweighted average increase from Oriental to continental US Chinese was about 38% and 34% for E1 and E2, respectively. On the other hand, levels of E3 decreased from the low-risk to the high-risk group, but the decrease was modest (16%) and not always regular. There were no systematic or significant differences in the frequency of ovulation in the three groups of women. These results are compatible with the hypothesis that high levels of estrone and estradiol are important to breast carcinogenesis. Whether E3 has some additional "protective" effect or is irrelevant is unclear. The data do not support the hypothesis that total urine estrogens (E1 + E2 + E3) are predictive of population groups at high risk for breast cancer and they appear inconsistent with the hypothesis that frequency of ovulation (or anovulation) is an important aspect of breast carcinogenesis.
Published: 2016
Full Text: View/download PDF

2. Investigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?

Author: Stéphane Bretagne, Alexandre Alanio, Dea Garcia-Hermoso, Marie Desnos-Ollivier, Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Subjects: 0301 basic medicine, Microbiology (medical), MESH: Fungi, Genotype, Epidemiology, short tandem repeat, 030106 microbiology, yeasts, multilocus sequence typing, Review, endemic mycoses, Biology, MESH: Epidemiologic Methods, MESH: Genotype, 03 medical and health sciences, molds, MESH: Mycoses, microsatellite length polymorphism, Humans, Coding region, Pneumocystis jirovecii, Scedosporium spp, Typing, Genotyping, Candida spp, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Genetics, Cross Infection, MESH: Humans, General Immunology and Microbiology, Fungi, Public Health, Environmental and Occupational Health, Reproducibility of Results, Outbreak, MESH: Cross Infection, Fusarium spp, biology.organism_classification, Housekeeping gene, Aspergillus spp, MESH: Reproducibility of Results, Infectious Diseases, MESH: Multilocus Sequence Typing, Mycoses, genotyping, Cryptococcus neoformans, Multilocus sequence typing, Microsatellite, Epidemiologic Methods
Abstract: SUMMARY Genotyping studies of medically important fungi have addressed elucidation of outbreaks, nosocomial transmissions, infection routes, and genotype-phenotype correlations, of which secondary resistance has been most intensively investigated. Two methods have emerged because of their high discriminatory power and reproducibility: multilocus sequence typing (MLST) and microsatellite length polymorphism (MLP) using short tandem repeat (STR) markers. MLST relies on single-nucleotide polymorphisms within the coding regions of housekeeping genes. STR polymorphisms are based on the number of repeats of short DNA fragments, mostly outside coding regions, and thus are expected to be more polymorphic and more rapidly evolving than MLST markers. There is no consensus on a universal typing system. Either one or both of these approaches are now available for Candida spp., Aspergillus spp., Fusarium spp., Scedosporium spp., Cryptococcus neoformans , Pneumocystis jirovecii , and endemic mycoses. The choice of the method and the number of loci to be tested depend on the clinical question being addressed. Next-generation sequencing is becoming the most appropriate method for fungi with no MLP or MLST typing available. Whatever the molecular tool used, collection of clinical data (e.g., time of hospitalization and sharing of similar rooms) is mandatory for investigating outbreaks and nosocomial transmission.
Published: 2017
Full Text: View/download PDF

3. Item reduction based on rigorous methodological guidelines is necessary to maintain validity when shortening composite measurement scales

Author: Jacques Pouchot, Christophe Goetz, Anne-Christine Rat, Joël Coste, Marc Debouverie, Fabienne Lemétayer, Elisabeth Spitz, Sophie Recchia, Francis Guillemin, Sébastien Montel, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), and University of Luxembourg [Luxembourg]
Subjects: Research design, Psychometrics, Epidemiology, Computer science, media_common.quotation_subject, Statistics as Topic, Guidelines as Topic, MESH: Epidemiologic Methods, 03 medical and health sciences, 0302 clinical medicine, MESH: Psychometrics, Humans, MESH: Data Collection, 030212 general & internal medicine, MESH: Statistics as Topic, media_common, MESH: Humans, Data collection, Data Collection, MESH: Research Design, MESH: Guidelines as Topic, Reproducibility of Results, Reliability engineering, MESH: Reproducibility of Results, Clinical Practice, Measurement scales, Research Design, Current practice, Item reduction, Conceptual model, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Epidemiologic Methods, 030217 neurology & neurosurgery
Abstract: Objective To review current practice and update guidelines for the methodology of shortening composite measurement scales (CMSs). Study Design and Setting A literature review gathered data on 91 shortening processes from 1995 to 2009. The validity of the initial CMS, the shortening methods, and the validity of the derived short-form scales were examined. The results were compared with those from a previous literature review (articles from 1985 to 1995) to develop updated guidelines for CMS shortening. Results The literature review revealed a persisting lack of use of rigorous methodology for CMS shortening. Of the 91 cases of CMS shortening, 36 combined a content approach and a statistical approach; 45 used only a statistical approach and 10 (11%) only a content approach. The updated guidelines deal with the validity and conceptual model of the initial CMS, the preservation of content and psychometric properties during shortening, the selection of items, and the validation of the short form. Conclusion Item reduction based on a rigorous methodology is necessary if the short-form instrument aims to maintain the validity and other measurement properties of the parent instrument, which in turn supports application in research and clinical practice.
Published: 2013
Full Text: View/download PDF

4. The epidemiology of cough

Author: Raphaëlle Varraso, Francine Kauffmann, Nadif, Rachel, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), The Egea study is supported by Hospital program of clinical research (PHRC)-‐Paris, Merck Sharp & Dohme (MSD), National Research Agency Health environment, health-‐work program, National Research Agency (ANR)-‐ Biological collections for health program, French Agency of health safety, environment and work (AFSSET). The E3N study is supported by the Mutuelle Générale de l'Education Nationale (MGEN), the European Community, the French League against Cancer (LNCC), the Gustave Roussy Institute (IGR), the National Institute for Health and Medical Research (Inserm) and General Councils of France., and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Subjects: Male, Pediatrics, MESH: Asthma, MESH: Epidemiologic Methods, 0302 clinical medicine, cough, Sex factors, Surveys and Questionnaires, Epidemiology, gender, MESH: Cough, genetics, Pharmacology (medical), 030212 general & internal medicine, education.field_of_study, Age Factors, Circadian Rhythm, 3. Good health, Europe, Female, epidemiology, France, environment, Pulmonary and Respiratory Medicine, medicine.medical_specialty, European community, Population, MEDLINE, 03 medical and health sciences, Sex Factors, MESH: Sex Factors, Environmental health, medicine, Humans, MESH: Circadian Rhythm, education, Respiratory health, Asthma, MESH: Age Factors, MESH: Humans, business.industry, Genetic heterogeneity, MESH: Questionnaires, MESH: Chronic Disease, Biochemistry (medical), medicine.disease, MESH: Male, respiratory tract diseases, MESH: France, 030228 respiratory system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Chronic Disease, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; Cough is a common symptom that affects a large proportion of the general population, but has been somewhat neglected in the epidemiological literature in the recent years. Various types of coughs are described based on life-long epidemiological surveys. Using published and unpublished data from three epidemiological studies (the European Community Respiratory Health survey, the French Epidemiological study on the Genetics and environment of asthma (EGEA) and the French E3N study), some specific aspects are discussed in detail. Phenotypic heterogeneity according to chronicity, or its productive nature, or its daytime or nocturnal characteristics are discussed. The association of cough with asthma and gender is described, together with its evolution over a 12-year period. The potential for genetic studies of cough is discussed.
Published: 2011
Full Text: View/download PDF

5. Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis

Author: Mouterde, G., Lukas, C., Logeart, I., Flipo, R. M., Rincheval, N., Daurès, J. P., Combe, B., Saraux, Alain, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service de rhumatologie[Lille], Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Centre d'Investigation Clinique (CIC - Brest), and Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, MESH: Synovitis, [SDV]Life Sciences [q-bio], MESH: Epidemiologic Methods, Logistic regression, Arthritis, Rheumatoid, 0302 clinical medicine, MESH: Early Diagnosis, MESH: Autoantibodies, Immunology and Allergy, MESH: HLA-DRB1 Chains, MESH: Aged, MESH: Arthritis, Rheumatoid, 0303 health sciences, Univariate analysis, Synovitis, MESH: Middle Aged, medicine.diagnostic_test, Middle Aged, Prognosis, 3. Good health, MESH: Young Adult, Rheumatoid arthritis, Erythrocyte sedimentation rate, Cohort, Disease Progression, Female, MESH: Disease Progression, Seasons, Adult, medicine.medical_specialty, MESH: Rheumatoid Factor, Immunology, MESH: Arthritis, Blood Sedimentation, Peptides, Cyclic, MESH: Prognosis, General Biochemistry, Genetics and Molecular Biology, Young Adult, 03 medical and health sciences, Rheumatology, Rheumatoid Factor, Internal medicine, medicine, Humans, Rheumatoid factor, MESH: Blood Sedimentation, MESH: Peptides, Cyclic, Aged, Autoantibodies, 030304 developmental biology, 030203 arthritis & rheumatology, MESH: Humans, Receiver operating characteristic, business.industry, Arthritis, MESH: Biological Markers, MESH: Adult, HLA-DR Antigens, MESH: HLA-DR Antigens, medicine.disease, MESH: Male, Surgery, Radiography, Early Diagnosis, Epidemiologic Methods, business, MESH: Female, MESH: Seasons, Biomarkers, HLA-DRB1 Chains
Abstract: International audience; OBJECTIVES: To determine predictors of short-term radiographic progression in an inception cohort of patients with early arthritis. METHODS: Patients presenting with synovitis of at least two joints for 6 weeks to 6 months were included in the Etude et Suivi des POlyarthrites Indifferenciées Récentes (ESPOIR) cohort. Univariate analysis was used to determine the relationship between baseline variables and radiographic outcome (assessed by the modified total Sharp score (mTSS)) after 6 and 12 months. Stepwise multiple logistic regression was used to select independent predictive factors. The sensitivity and specificity of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) at baseline in discriminating between erosive and non-erosive disease were determined by receiver operating characteristic (ROC) curves. RESULTS: From data available for 736 patients, radiographic progression at 6 months was independently predicted by baseline ACPA, human leucocyte antigen (HLA)-DRB1*01 and/or 04 genes, erythrocyte sedimentation rate and mTSS. Interestingly, the season of onset of the first symptoms was associated with the severity of early arthritis (OR 1.66, 95% CI 1.07 to 2.59, in winter and spring vs summer and autumn). Univariate analysis revealed similar results for season at 12 months (OR 1.68, 95% CI 1.20 to 2.37). The peak of the ROC curves for radiographic outcome occurred with ACPA and RF values similar to the cut-offs provided by manufacturers. CONCLUSION: The authors found the onset of arthritis symptoms during winter or spring associated with greater radiographic progression at 6 months for patients with early arthritis. These data could reinforce the role of environmental factors in the development and outcome of rheumatoid arthritis.
Published: 2011
Full Text: View/download PDF

6. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Author: Pralay Mukhopadyay, Jacek Jassem, Fernando Hurtado de Mendoza, Eva Thomas, Hyun Cheol Chung, Henri Roché, Valorie F. Chan, Rubi K. Li, Luis Fein, Xavier Pivot, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), St. Luke's Medical Center, Kaiser Permanente, Yonsei Cancer Center, Centro de Oncologia Rosario, Veterans Memorial Medical Center, Medical University of Gdansk, Hospital Nacional Edgardo Rebagliati Martins, Bristol-Myers Squibb Company, Département d'oncologie médicale, Institut Claudius Regaud, Saas, Philippe, Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Cancer Research, Lung Neoplasms, Estrogen receptor, MESH: Epidemiologic Methods, Deoxycytidine, chemistry.chemical_compound, 0302 clinical medicine, MESH: Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols, skin and connective tissue diseases, MESH: Treatment Outcome, MESH: Antimetabolites, Antineoplastic, 0303 health sciences, Liver Neoplasms, Ixabepilone, Metastatic breast cancer, MESH: Drug Resistance, Neoplasm, 3. Good health, ErbB Receptors, MESH: Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Receptors, Estrogen, Oncology, 030220 oncology & carcinogenesis, MESH: Receptors, Estrogen, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Fluorouracil, Breast disease, Receptors, Progesterone, medicine.drug, MESH: Receptors, Progesterone, Antimetabolites, Antineoplastic, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Antineoplastic Agents, Breast Neoplasms, MESH: Receptor, Epidermal Growth Factor, Biology, 03 medical and health sciences, Breast cancer, Internal medicine, Progesterone receptor, Biomarkers, Tumor, medicine, Humans, MESH: Epothilones, Capecitabine, 030304 developmental biology, MESH: Humans, MESH: Deoxycytidine, Cancer, medicine.disease, MESH: Lung Neoplasms, Endocrinology, chemistry, Drug Resistance, Neoplasm, Epothilones, MESH: Tumor Markers, Biological, Cancer research, MESH: Antineoplastic Agents, Epidemiologic Methods, MESH: Female, MESH: Fluorouracil, MESH: Breast Neoplasms, Tamoxifen
Abstract: International audience; Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.
Published: 2009
Full Text: View/download PDF

7. Incidence and prognostic significance of sustained ventricular tachycardias in heart failure patients implanted with biventricular pacemakers without a back-up defibrillator: results from the prospective, multicentre, Mona Lisa cohort study

Author: Marie Lambiez, Nicolas Delarche, Serge Boveda, Eloi Marijon, D. Pavin, Pascal Defaye, Philippe Chevalier, Alan Bulava, Jobst B. Winter, Jean Paul Albenque, Nicolas Combes, Alexander Teubl, Daniel Gras, Sophie Jacob, Clinique Pasteur et Groupe Rythmologie Stimulation Cardiaque/SFC, Clinique Pasteur [Toulouse], Radiobiologie et épidémiologie (DRPH/SRBE), Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Cardiac Stimulation and Rhythmology, CHU Grenoble, Service de cardiologie et maladies vasculaires, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service de cardiologie, Hôpital Est -Lyon, The study was financed by Guidant., Mona Lisa Study Group, Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], and CHU Pontchaillou [Rennes]
Subjects: Male, Pacemaker, Artificial, medicine.medical_treatment, 030204 cardiovascular system & hematology, MESH: Epidemiologic Methods, Ventricular tachycardia, law.invention, Sudden cardiac death, MESH: Cause of Death, MESH: Aged, 80 and over, 0302 clinical medicine, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, law, Cause of Death, 030212 general & internal medicine, Aged, 80 and over, MESH: Aged, Cardiac resynchronization therapy, MESH: Middle Aged, Incidence, Mortality rate, Cardiac Pacing, Artificial, Middle Aged, Prognosis, MESH: Electrophysiologic Techniques, Cardiac, 3. Good health, MESH: Pacemaker, Artificial, Cardiology, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Electrophysiologic Techniques, Cardiac, Cardiology and Cardiovascular Medicine, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Cohort study, medicine.medical_specialty, Defibrillation, Heart failure, MESH: Cardiac Pacing, Artificial, MESH: Prognosis, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Humans, Aged, Electrograms, MESH: Humans, business.industry, MESH: Death, Sudden, Cardiac, medicine.disease, MESH: Male, Death, Sudden, Cardiac, MESH: Heart Failure, Tachycardia, Ventricular, Artificial cardiac pacemaker, MESH: Tachycardia, Ventricular, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; AIMS: The aim of this study was to investigate the 12-month incidence, predictive factors, and prognosis of sustained ventricular tachycardia (VT) in chronic heart failure patients implanted with biventricular pacemakers without a back-up defibrillator (CRT-P), assessed by continuous intracardiac ventricular electrograms. METHODS AND RESULTS: The Mona Lisa study, a prospective, multicentre, cohort study, designed to determine the incidence of sustained VT and its prognostic impact in CRT-P recipients within the year after implant enrolled 198 patients with moderate or severe chronic heart failure, despite optimal pharmacological therapy. An independent committee reviewed the data from all arrhythmic episodes as well as causes of death according to predefined criteria. During a mean follow-up of 9.8 +/- 3.1 months after implantation, 8 patients experienced at least one episode of sustained VT [4.3%; 95% confidence interval (CI), 1.1-7.5] and 21 deaths occurred, giving a 12-month mortality rate of 11.7% (95% CI, 6.4-16.9). The presence of sustained VT was associated with a high risk of sudden cardiac death (SCD) and the lowest 12-month overall survival (P < 0.0001). CONCLUSION: The incidence of sustained VT remains relatively low in the first year after CRT-P implantation, but when present appears closely associated with short-term adverse outcomes, especially SCD. This emphasizes the possible value of remote monitoring to detect high-risk patients for urgent upgrading.
Published: 2009
Full Text: View/download PDF

8. Validation of an echocardiographic multiparametric strategy to increase responders patients after cardiac resynchronization: a multicentre study

Author: Frédéric Franceschi, Gilbert Habib, Hasnaa Belghiti, Jean-Claude Deharo, Antoine Deplagne, Erwan Donal, Pierre Dos Santos, Raymond Roudaut, Stéphane Lafitte, Julie Chabaneix, Pierre Bordachar, Jacques Clementy, Aude Mignot, Hannan Bougted, P. Reant, Christophe Leclercq, Amira Zaroui, Département de cardiologie, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Adaptation cardiovasculaire à l'ischemie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Service de cardiologie, and Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)
Subjects: Male, medicine.medical_treatment, Mean QRS Duration, 030204 cardiovascular system & hematology, MESH: Epidemiologic Methods, MESH: Stroke Volume, Ventricular Dysfunction, Left, MESH: Aged, 80 and over, 0302 clinical medicine, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Mitral valve, MESH: Ventricular Dysfunction, Left, 030212 general & internal medicine, Ultrasonography, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Ejection fraction, Cardiac Pacing, Artificial, Stroke volume, Middle Aged, medicine.anatomical_structure, Echocardiography, cardiovascular system, Cardiology, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Cardiology and Cardiovascular Medicine, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Algorithms, medicine.medical_specialty, Cardiac resynchronization therapy, Heart failure, MESH: Algorithms, MESH: Cardiac Pacing, Artificial, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Cardiac resynchronization, Internal medicine, medicine, Humans, cardiovascular diseases, Systole, Ventricular dyssynchrony, Aged, MESH: Humans, business.industry, Stroke Volume, medicine.disease, MESH: Male, MESH: Heart Failure, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; AIMS: We sought to develop and validate a multiparametric algorithm by applying previously validated criteria to predict cardiac resynchronization therapy (CRT) response in a multicentre study. Thirty per cent of patients treated by CRT fail to respond to the treatment. Although dyssynchrony by echocardiography has been used to improve the selection of patients, the complexity of myocardial contraction has generated a moderate improvement using any of several individual parameters. METHODS AND RESULTS: Two hundred end-stage heart failure patients [NYHA 3-4 and left ventricular ejection fraction (LVEF)120 ms were included. Echocardiography analysis focused on the following parameters: atrioventricular dyssynchrony, interventricular dyssynchrony, and intraventricular dyssynchrony that integrated radial (PSAX M-mode) and longitudinal [tissue Doppler imaging (TDI)] evaluations for spatial (wall to wall) and temporal (wall end-systole to mitral valve opening) dyssynchrony diagnosis. Following CRT implantation, patients were monitored for 6 months with functional and echo evaluations defining responders by a 15% reduction in end-systolic volume. Mean QRS duration and LVEF were 152 +/- 17 ms and 25 +/- 8%. There was a CRT response in 57% of patients, independent of QRS width. Mean prevalence of positive criteria was 34 +/- 8%. Feasibility and variability averages were 81 +/- 20% and 9 +/- 4%. In a single parametric approach, ranges of sensitivities and specificities were 18-65% and 45-84% with a mean of 41% and 66%. A multiparametric approach by focusing on criteria combination decreased the mean rate of false-positive results to 14 +/- 12%, 5 +/- 4%, 2 +/- 2%, and 1 +/- 2% from one to four parameters, respectively. More than three parameters were associated with a specificity above 90% and a positive predictive value above 65%. Reproducibility of this global strategy was 91%. CONCLUSION: A multiparametric echocardiographic strategy based on the association of conventional criteria is a better indicator of CRT response than the existing single parametric approaches.
Published: 2009
Full Text: View/download PDF

9. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

Author: A. Sarah Walker, Osamah Hamouda, Virginie Rondeau, Maria Dorrucci, Heiner C. Bucher, Maria Prins, Geneviève Chêne, Kholoud Porter, Caroline A. Sabin, Rodolphe Thiébaut, Benoît Marin, Dominique Costagliola, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Basel Institute for Clinical Epidemiology, University Hospital Basel [Basel], Epidémiologie Clinique et Traitement de l'Infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento di Malattie Infettive, Reparto di Epidemiologia, Istituto Superiore di Sanita [Rome], Department of Infectious Disease Epidemiology, Robert Koch Institute [Berlin] (RKI), Cluster Infectious Diseases, Amsterdam BioMed Cluster, Medical Research Council Clinical Trials Unit (MRC CTU), University College of London [London] (UCL), Research Department of Infection and Population Health [London], CASCADE has been funded through grants from the European Union BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708 and LSHP-CT-2006-018949., Istituto Superiore di Sanità (ISS), AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Infectious diseases
Subjects: Male, MESH: CD4 Lymphocyte Count, medicine.medical_treatment, CD4 cell count, Disease, MESH: Epidemiologic Methods, MESH: Antiretroviral Therapy, Highly Active, Hepatitis, Liver disease, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Neoplasms, Immunology and Allergy, MESH: Neoplasms, 030212 general & internal medicine, Causes of death, Immunodeficiency, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH: AIDS-Related Opportunistic Infections, Liver Diseases, Immunosuppression, Middle Aged, Human Immunodeficiency Virus/AIDS, Antiretroviral therapy, 3. Good health, Infectious Diseases, Cardiovascular Diseases, MESH: Young Adult, Female, Viral disease, Adult, medicine.medical_specialty, MESH: Immune Tolerance, MESH: Liver Diseases, Adolescent, Immunology, Article, Young Adult, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Internal medicine, Immune Tolerance, medicine, Humans, Seroconversion, highly active, Aged, MESH: Acquired Immunodeficiency Syndrome, MESH: Adolescent, Acquired Immunodeficiency Syndrome, MESH: Humans, AIDS-Related Opportunistic Infections, 030306 microbiology, business.industry, MESH: Cardiovascular Diseases, MESH: Adult, medicine.disease, MESH: Male, CD4 Lymphocyte Count, Neoplasm, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Bacterial infection, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). DESIGN: Observational multicentre cohorts. METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification. RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.
Published: 2009
Full Text: View/download PDF

10. Serological prevalence of echinococcosis and risk factors for infection among children in rural communities of southern Ningxia, China

Author: Philip S. Craig, Ling Huang, Jing Teng, Tao Sun, Gail M. Williams, Wei Zhang, Malcolm K. Jones, Yu Rong Yang, Belgees Boufana, Dominique A. Vuitton, Patrick Giraudoux, Donald P. McManus, Yanbin Li, Tian Xi Liu, Ningxia Medical College, Biomedical Sciences Research Institute, University of Salford, WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, SERF Unit, Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ), Molecular Parasitology Unit, University of Queensland [Brisbane]-The Queensland Institute of Medical Research-Australian Centre for International and Tropical Health and Nutrition ( ACITH ), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), and Queensland Institute of Medical Research-University of Queensland [Brisbane]-Australian Centre for International and Tropical Health and Nutrition (ACITH)
Subjects: Prevalence, Rural Health, MESH : Echinococcus multilocularis, MESH: Epidemiologic Methods, MESH : Echinococcosis, MESH: Echinococcus granulosus, 030308 mycology & parasitology, 0302 clinical medicine, MESH : Child, Risk Factors, MESH: Risk Factors, MESH: Child, MESH : Rural Health, MESH : Socioeconomic Factors, MESH: Animals, Child, Echinococcus granulosus, 0303 health sciences, biology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Risk Factors, Echinococcosis, MESH: China, 3. Good health, [ SDE.MCG ] Environmental Sciences/Global Changes, Infectious Diseases, China, MESH: Socioeconomic Factors, Adolescent, [SDE.MCG]Environmental Sciences/Global Changes, 030231 tropical medicine, Helminthiasis, MESH : Family Health, Echinococcus multilocularis, MESH : Epidemiologic Methods, MESH: Echinococcosis, 03 medical and health sciences, MESH : Adolescent, Environmental health, parasitic diseases, medicine, Animals, Humans, MESH : China, Seroprevalence, Risk factor, Family Health, MESH: Adolescent, MESH: Echinococcus multilocularis, MESH: Humans, MESH : Echinococcus granulosus, business.industry, MESH : Humans, Public Health, Environmental and Occupational Health, MESH: Rural Health, medicine.disease, biology.organism_classification, Echinococcus, Socioeconomic Factors, MESH: Family Health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Parasitology, MESH : Animals, Epidemiologic Methods, business
Abstract: International audience; OBJECTIVE: To assess the usefulness of serology as an indicator of Echinococcus transmission for developing preventive measures against echinococcosis in rural communities. METHODS: Cross-sectional survey in 2002 among 861 children aged 7 to 18 years in Xiji County, Ningxia, China. Before ultrasound abdominal examination, a questionnaire was used to identify socioeconomic, sanitary and hygiene risk factors for echinococcal infection; filter paper blood samples were collected from each child for specific antibody detection using EmP (Echinococcus multilocularis) and EgB (Echinococcus granulosus) antigens. RESULTS: Transmission of both E. multilocularis and E. granulosus occur in this area. Serological prevalence was far higher than disease prevalence in this age range. We found no gender-related differences of seroprevalence among the children, suggesting an equal chance of exposure to echinococcal egg-contaminated environments. The seroprevalence distribution was associated with changes in the ecology of wild hosts for E. multilocularis contamination, and with changes in socio-geographic features of the communities for E. granulosus contamination. CONCLUSIONS: Serological data obtained for children in mass surveys of echinococcosis appear to be a comprehensive and useful tool to monitor changes of transmission dynamics in humans and provide 'warning signals' to decision makers for the instigation of specific control measures against the disease.
Published: 2008
Full Text: View/download PDF

11. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study

Author: Valérie Hahn-Barma, Bruno Dubois, Jean-Charles Lambert, Dominique Campion, Serge Bakchine, Agnès Camuzat, Christine Van Broeckhoven, Serge Belliard, Michèle Puel, Patrice Verpillat, Eric Guedj, Alexis Brice, Fabienne Clot, Marie-Odile Habert, Isabelle Le Ber, Jacqueline Mikol, Pascal Lejeune, Ftd-Mnd, Julie van der Zee, Mustapha Ghanim, Didier Hannequin, Vincent Deramecourt, Christian Meyrignac, Martine Vercelletto, Anne Rovelet-Lecrux, Florence Pasquier, Lucette Lacomblez, Vincent de La Sayette, Neurologie et thérapeutique expérimentale, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), Génétique médicale et fonctionnelle du cancer et des maladies neuropsychiatriques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Department of Genetics, University Hospital, Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service Central de Biophysique et de Médecine Nucléaire, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre des Maladies Cognitives et Comportementales [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Antwerpen, Université de Reims Champagne-Ardenne (URCA), Neurologie générale et maladies inflammatoires du système nerveux [Toulouse], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Fédération des Maladies du Système Nerveux, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d′Anatomie et de Cytologie Pathologiques [Lariboisiere], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neuroendocrinologie et physiopathologie neuronale, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Centre Hospitalier Intercommunal, Centre Hospitalier Départemental, Laboratoire de Neuropsychologie, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Clinique neurologique, Hôpital Laennec, Service de neurologie, Epidémiologie des maladies chroniques : impact des interactions gène environnement sur la santé des populations, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Laboratoire d'Imagerie Fonctionnelle (LIF), Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR14-IFR49-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine nucléaire [CHU Pitié-Salpétrière], Neuro-anatomie fonctionnelle du comportement et de ses troubles, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre du Langage et de Neuropsychologie, Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), ANR-06-MRAR-005-01, ANR, Département de neurologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Normandie Université (NU)-Normandie Université (NU)-École Pratique des Hautes Études (EPHE), Université de Rennes (UR), French research Network on FTD/FTD-MND, and Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: Male, Pathology, Neuropsychological Tests, MESH: Epidemiologic Methods, MESH: Aphasia, Primary Progressive, Apraxia, MESH: Magnetic Resonance Imaging, Primary progressive aphasia, Progranulins, MESH: Aged, 80 and over, 0302 clinical medicine, MESH: Motor Neuron Disease, Corticobasal degeneration, Age of Onset, MESH: Brain Mapping, MESH: Heterozygote, Aged, 80 and over, MESH: Aged, Brain Mapping, 0303 health sciences, MESH: Middle Aged, Parkinsonism, Brain, MESH: Neuropsychological Tests, Middle Aged, Magnetic Resonance Imaging, MESH: Dementia, 3. Good health, Phenotype, Disease Progression, Intercellular Signaling Peptides and Proteins, Female, MESH: Disease Progression, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Psychology, Haploinsufficiency, Frontotemporal dementia, Adult, Heterozygote, medicine.medical_specialty, MESH: Mutation, MESH: Age of Onset, MESH: Phenotype, MESH: Brain, 03 medical and health sciences, medicine, Humans, Dementia, Motor Neuron Disease, MESH: Intercellular Signaling Peptides and Proteins, Aged, 030304 developmental biology, MESH: Humans, Lewy body, MESH: Adult, medicine.disease, MESH: Male, MESH: Cognition Disorders, Aphasia, Primary Progressive, Mutation, Neurology (clinical), Cognition Disorders, Epidemiologic Methods, MESH: Female, 030217 neurology & neurosurgery
Abstract: Frontotemporal dementia (FTD), characterized by behavioural and language disorders, is a clinically, genetically and pathologically heterogeneous group of diseases. The most recently identified of the four known genes is GRN, associated with 17q-linked FTD with ubiquitin-immunoreactive inclusions. GRN was analysed in 502 probands with frontal variant FTD (fvFTD), FTD with motoneuron disease (FTD-MND), primary progressive aphasia (PPA) and corticobasal degeneration syndrome (CBDS). We studied the clinical, neuropsychological and brain perfusion characteristics of mutation carriers. Eighteen mutations, seven novel were found in 24 families including 32 symptomatic mutation carriers. No copy number variation was found. The phenotypes associated with GRN mutations vary greatly: 20/32 (63%) carriers had fvFTD, the other (12/32, 37%) had clinical diagnoses of PPA, CBDS, Lewy body dementia or Alzheimer's disease. Parkinsonism developed in 13/32 (41%), visual hallucinations in 8/32 (25%) and motor apraxia in 5/21 (24%). Constructional disorders were present in 10/21 (48%). Episodic memory disorders were frequent (16/18, 89%), consistent with hippocampal amnestic syndrome in 5/18 (28%). Hypoperfusion was observed in the hippocampus, parietal lobe and posterior cingulate gyrus, as well as the frontotemporal cortices. The frequency of mutations according to phenotype was 5.7% (20/352) in fvFTD, 17.9% (19/106) in familial forms, 4.4% in PPA (3/68), 3.3% in CBDS (1/30). Hallucinations, apraxia and amnestic syndrome may help differentiate GRN mutation carriers from others FTD patients. Variable phenotypes and neuropsychological profiles, as well as brain perfusion profiles associated with GRN mutations may reflect different patterns of neurodegeneration. Since all the mutations cause a progranulin haploinsufficiency, additional factors probably explain the variable clinical presentation of the disease.
Published: 2008
Full Text: View/download PDF

12. Household exposure to pesticides and risk of childhood acute leukaemia

Author: Brigitte Nelken, Florence Menegaux, André Baruchel, Brigitte Lescoeur, Yves Bertrand, Denis Hémon, Danièle Sommelet, Guy Leverger, Jacqueline Clavel, Recherches épidémiologiques et statistiques sur l'environnement et la santé., Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie pédiatrique, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service pédiatrique d'hématologie, Hospices Civils de Lyon (HCL)-Hôpital Debrousse, Hospices Civils de Lyon (HCL), Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service pédiatrique d'hématologie-oncologie, Hôpital Jeanne de Flandre [Lille], Service d'Hématologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Kaniewski, Nadine
Subjects: Male, Insecticides, Pediculosis, Ethnic origin, 010501 environmental sciences, MESH: Epidemiologic Methods, 01 natural sciences, MESH: Pregnancy, 0302 clinical medicine, Pregnancy, MESH: Child, Epidemiology, MESH: Maternal Exposure, Child, Acute leukemia, Leukemia, MESH: Infant, Newborn, Environmental exposure, Lice Infestations, MESH: Prena, MESH: Infant, 3. Good health, Maternal Exposure, Child, Preschool, Prenatal Exposure Delayed Effects, 030220 oncology & carcinogenesis, Acute Disease, Paternal Exposure, MESH: Acute Disease, Female, Original Article, medicine.medical_specialty, Adolescent, MESH: Environmental Exposure, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Environmental health, MESH: Leukemia, medicine, Humans, MESH: Pesticides, Pesticides, Risk factor, 0105 earth and related environmental sciences, MESH: Adolescent, MESH: Paternal Exposure, MESH: Humans, business.industry, MESH: Child, Preschool, Infant, Newborn, MESH: Lice Infestations, Public Health, Environmental and Occupational Health, Infant, Environmental Exposure, Odds ratio, medicine.disease, MESH: Male, MESH: Insecticides, Surgery, Scalp Dermatoses, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; OBJECTIVES: To investigate the relation between childhood acute leukaemia and household exposure to pesticides. METHODS: The study included 280 incident cases of acute leukaemia and 288 controls frequency matched on gender, age, hospital, and ethnic origin. The data were obtained from standardised face to face interviews of the mothers with detailed questions on parental occupational history, home and garden insecticide use, and insecticidal treatment of pediculosis. Odds ratios were estimated using unconditional regression models including the stratification variables parental socioeconomic status and housing characteristics. RESULTS: Acute leukaemia was observed to be significantly associated with maternal home insecticide use during pregnancy (OR = 1.8, 95% CI 1.2 to 2.8) and during childhood (OR = 1.7, 95% CI 1.1 to 2.4), with garden insecticide use (OR = 2.4, 95% CI 1.3 to 4.3), and fungicide use (OR = 2.5, 95% CI 1.0 to 6.2) during childhood. Insecticidal shampoo treatment of pediculosis was also associated with childhood acute leukaemia (OR = 1.9, 95% CI 1.2 to 3.3). CONCLUSION: The results reported herein support the hypothesis that various types of insecticide exposure may be a risk factor for childhood acute leukaemia. The observed association with insecticidal shampoo treatment of pediculosis, which has never been investigated before, requires further study.
Published: 2006
Full Text: View/download PDF

13. Weight change and changes in the metabolic syndrome as the French population moves towards overweight: The D.E.S.I.R. Cohort

Author: Anne Fagot-Campagna, M. Cailleau, Sylviane Vol, Beverley Balkau, Eveline Eschwège, Teresa A. Hillier, Epidémiologie cardiovasculaire et métabolique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Institut inter-Régional pour la SAnté (IRSA), and DESIR cohort
Subjects: Blood Glucose, Male, Epidemiology, Physiology, Blood Pressure, MESH: Epidemiologic Methods, Weight Gain, MESH: Health Surveys, 0302 clinical medicine, MESH: Metabolic Syndrome X, Weight loss, Insulin, Medicine, 030212 general & internal medicine, Metabolic Syndrome, education.field_of_study, MESH: Middle Aged, MESH: Blood Pressure, General Medicine, Middle Aged, 3. Good health, Cohort, MESH: Weight Gain, Body Composition, Female, France, MESH: Cholesterol, HDL, medicine.symptom, MESH: Triglycerides, Adult, medicine.medical_specialty, Waist, Population, 030209 endocrinology & metabolism, MESH: Insulin, Article, 03 medical and health sciences, Internal medicine, Humans, MESH: Overweight, education, National Cholesterol Education Program, Triglycerides, MESH: Humans, business.industry, Cholesterol, HDL, Weight change, MESH: Adult, MESH: Body Composition, Overweight, medicine.disease, Health Surveys, MESH: Male, MESH: France, Endocrinology, MESH: Blood Glucose, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Metabolic syndrome, Epidemiologic Methods, business, MESH: Female, Weight gain
Abstract: International audience; BACKGROUND: How weight change affects the metabolic syndrome (MS) and its parameters is unknown, particularly, in a leaner European population such as the French prospective D.E.S.I.R. cohort. METHODS: In 3770 D.E.S.I.R. participants (sex ratio=1) averaging 47.5 years (range 30-64), with measured weight and MS parameters at baseline (D0) and at 6 year follow-up (D6), we assessed this relationship across five weight-change classes, using stable weight as the referent group (-2 to +2 kg). We used analysis-of-covariance to assess changes in each MS parameter and logistic regression to assess incident MS, according to the National Cholesterol Education Program (NCEP). We also assessed weight-change effect on MS status between D0 and D6. RESULTS: At D0, average weight was 68.4 kg (SD 12.3); BMI was 24.8 kg/m2 (SD 3.5). From D0-D6, the cohort gained a mean 2.1 kg (median 2.0; SD 4.4). After adjustment for age and D0 weight, there was a strong linear relationship with weight change and worsening of the following MS parameters at D6: fasting insulin, waist girth, fasting glucose, fasting triglycerides, HDL cholesterol, and systolic and diastolic blood pressure (P9 kg; 10% of those who lost >2 kg reverted to non-NCEP-MS. CONCLUSIONS: All continuous MS measures are linearly related to weight change, and MS can resolve with modest weight loss, underscoring the importance of maintaining lifelong normal weight.
Published: 2005
Full Text: View/download PDF

14. Nationwide outbreak of Salmonella enterica serotype 4,[5],12:i:- infection associated with consumption of dried pork sausage, France, November to December 2011

Author: E Terrien, V Dusch, S Tessier, N Jourdan-da Silva, S. Le Hello, C Janin, D. Van Cauteren, Anne Brisabois, François-Xavier Weill, Véronique Vaillant, Céline M Gossner, European Centre for Disease Prevention and Control (ECDC), Institut de Veille Sanitaire (INVS), Centre National de Référence - National Reference Center Escherichia coli, Shigella et Salmonella (CNR-ESS), Institut Pasteur [Paris], PROFET, INVS, Laboratoire de sécurité des aliments de Maisons-Alfort (LSAl), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Maisons des urgences sanitaires, Direction Générale de l'Alimentation (DGAL), Ministère de l'agriculture, de l'agroalimentaire et de la forêt-Ministère de l'agriculture, de l'agroalimentaire et de la forêt, European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), and Institut Pasteur [Paris] (IP)
Subjects: Serotype, Male, Veterinary medicine, Epidemiology, Swine, MESH: Epidemiologic Methods, Disease Outbreaks, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Child, Medicine, MESH: Animals, 030212 general & internal medicine, MESH: Incidence, MESH: Disease Outbreaks, Child, MESH: Swine, 2. Zero hunger, MESH: Meat, MESH: Aged, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, biology, Incidence, MESH: Infant, Newborn, Salmonella enterica, Middle Aged, MESH: Infant, 3. Good health, MESH: Salmonella enterica, MESH: Young Adult, Child, Preschool, Female, Salmonella Food Poisoning, France, Adult, Meat, Adolescent, 03 medical and health sciences, Young Adult, Virology, Food microbiology, Animals, Humans, Serotyping, MESH: Food Microbiology, Pork sausage, Aged, MESH: Adolescent, MESH: Salmonella Food Poisoning, MESH: Humans, 030306 microbiology, business.industry, MESH: Child, Preschool, Public Health, Environmental and Occupational Health, Infant, Newborn, Outbreak, MESH: Serotyping, Infant, MESH: Adult, biology.organism_classification, Infant newborn, MESH: Male, MESH: France, Food Microbiology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Epidemiologic Methods, MESH: Female
Abstract: International audience; An outbreak of the monophasic variant of Salmonella enterica serotype 4,[5],12:i:- occurred in November and December 2011 in France. Epidemiological investigation and food investigation with the help of supermarket loyalty cards suggested dried pork sausage from one producer as the most likely source of the outbreak. Despite the absence of positive food samples, control measures including withdrawal and recall were implemented.
Published: 2012
Full Text: View/download PDF

15. Timing of onset of cognitive decline: Results from Whitehall II prospective cohort study

Author: Aline Dugravot, Alexis Elbaz, Claudine Berr, Klaus P. Ebmeier, Mika Kivimäki, Maria Lee Glymour, Archana Singh-Manoux, Jane E. Ferrie, Schmaus, Annie, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Epidemiology and Public Health, University College of London [London] (UCL), Centre de Gérontologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ste Périne, Department of Society, Human Development, and Health, Harvard School of Public Health, Neuroépidémiologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centres Mémoire de Ressources et de Recherche Montpellier (CMRR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier], Department of Psychiatry, University of Oxford-Warneford Hospital, School of Social and Community Medicine [Bristol], University of Bristol [Bristol], ASM is supported by a 'European Young Investigator Award' from the European Science Foundation and the National Institute on Aging, NIH (R01AG013196, R01AG034454). MK is supported by the BUPA Foundation, the National Institutes of Health (R01HL036310, R01AG034454) and the Academy of Finland. The Whitehall II study is also supported by a grantfrom the British Medical Research Council (G0902037) and the British Heart Foundation., Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of Oxford [Oxford]-Warneford Hospital, and Warneford Hospital-University of Oxford [Oxford]
Subjects: Gerontology, Male, Aging, Neuropsychological Tests, MESH: Epidemiologic Methods, 0302 clinical medicine, London, Medicine, MESH: Aging, 030212 general & internal medicine, Age of Onset, Cognitive decline, Prospective cohort study, General Environmental Science, MESH: Aged, education.field_of_study, MESH: Middle Aged, General Engineering, MESH: Neuropsychological Tests, General Medicine, Middle Aged, Cognitive test, Cohort, Educational Status, Female, Adult, MESH: Age of Onset, Population, 03 medical and health sciences, Humans, education, Aged, MESH: Humans, business.industry, Research, MESH: Adult, MESH: London, MESH: Male, Middle age, Confidence interval, MESH: Cognition Disorders, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, General Earth and Planetary Sciences, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Age of onset, Epidemiologic Methods, MESH: Educational Status, business, Cognition Disorders, MESH: Female, 030217 neurology & neurosurgery
Abstract: International audience; OBJECTIVES: To estimate 10 year decline in cognitive function from longitudinal data in a middle aged cohort and to examine whether age cohorts can be compared with cross sectional data to infer the effect of age on cognitive decline. DESIGN: Prospective cohort study. At study inception in 1985-8, there were 10,308 participants, representing a recruitment rate of 73%. SETTING: Civil service departments in London, United Kingdom. PARTICIPANTS: 5198 men and 2192 women, aged 45-70 at the beginning of cognitive testing in 1997-9. MAIN OUTCOME MEASURE: Tests of memory, reasoning, vocabulary, and phonemic and semantic fluency, assessed three times over 10 years. RESULTS: All cognitive scores, except vocabulary, declined in all five age categories (age 45-49, 50-54, 55-59, 60-64, and 65-70 at baseline), with evidence of faster decline in older people. In men, the 10 year decline, shown as change/range of test × 100, in reasoning was -3.6% (95% confidence interval -4.1% to -3.0%) in those aged 45-49 at baseline and -9.6% (-10.6% to -8.6%) in those aged 65-70. In women, the corresponding decline was -3.6% (-4.6% to -2.7%) and -7.4% (-9.1% to -5.7%). Comparisons of longitudinal and cross sectional effects of age suggest that the latter overestimate decline in women because of cohort differences in education. For example, in women aged 45-49 the longitudinal analysis showed reasoning to have declined by -3.6% (-4.5% to -2.8%) but the cross sectional effects suggested a decline of -11.4% (-14.0% to -8.9%). CONCLUSIONS: Cognitive decline is already evident in middle age (age 45-49).
Published: 2012
Full Text: View/download PDF

16. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD

Author: Jérôme Boursier, Christine Cavaro-Menard, Julien Chaigneau, Vincent Roullier, Yves Gallois, Sandrine Bertrais, Marie Christine Rousselet, Paul Calès, Frédéric Oberti, Yves Deugnier, Fabrice Lainé, I. Hubert, Jeremy Sandrini, Gilles Hunault, Nina Dib, Sophie Michalak, Christophe Aubé, Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Département d'hépato-gastroentérologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), image, Laboratoire d'Ingéniérie des Systèmes Automatisés (LISA), Université d'Angers (UA)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Centre National de la Recherche Scientifique (CNRS), Fer et Métabolismes, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes]-CHU Pontchaillou [Rennes], Laboratoire de Pathologie Cellulaire et Tissulaire, Unité d'Investigation Clinique, Université d'Angers (UA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)-Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], and Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)
Subjects: Liver Cirrhosis, Male, nonalcoholic fatty liver disease, Cirrhosis, Chronic liver disease, MESH: Epidemiologic Methods, Gastroenterology, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Fibrosis, MESH: Metabolic Syndrome X, Nonalcoholic fatty liver disease, Medicine, MESH: Fatty Liver, MESH: Middle Aged, Biopsy, Needle, Fatty liver, Middle Aged, liver morphometry, 3. Good health, Liver, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, MESH: Liver Cirrhosis, Algorithms, Adult, medicine.medical_specialty, MESH: Biopsy, Needle, Hepatitis, Viral, Human, MESH: Algorithms, metabolic syndrome, liver steatosis, 03 medical and health sciences, Internal medicine, Image Interpretation, Computer-Assisted, Humans, MESH: Liver Diseases, Alcoholic, Liver Diseases, Alcoholic, MESH: Hepatitis, Viral, Human, Hepatitis, MESH: Humans, Hepatology, business.industry, fibrosis, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, MESH: Male, Fatty Liver, Steatosis, Metabolic syndrome, Epidemiologic Methods, business, MESH: Female, MESH: Image Interpretation, Computer-Assisted, MESH: Liver
Abstract: International audience; BACKGROUND AND AIM: We carried out morphometric measurements of steatosis to evaluate relationships between steatosis degree and other liver lesions or metabolic syndrome components in nonalcoholic fatty liver disease (NAFLD). PATIENTS AND METHODS: We developed an algorithm to measure steatosis area. Two hundred and fourteen patients with NAFLD were included in derivation (10) and validation (204) groups. Controls consisted of patients who were steatosis-free (12), patients with chronic hepatitis C (188), and patients with alcoholic chronic liver disease (94). RESULTS: Accuracy of steatosis area was considered as good or very good in at least 72% of cases by three pathologists. Steatosis areas were as follows: NAFLD = 10.3 ± 9.7%, virus = 2.4 ± 3.1%, alcohol = 7.8 ± 8.2% (P
Published: 2011
Full Text: View/download PDF

17. HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis

Author: Chung, Ho Yin, Machado, Pedro, Van Der Heijde, Désirée, D'Agostino, Maria-Antonietta, Dougados, Maxime, Saraux, Alain, Department of Rheumatology, University Hospital Maastricht, Service de Rhumatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Ambroise Paré, Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Cochin [AP-HP], Université de Brest (UBO) - IFR148, and Université de Brest (UBO) - Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, Settore MED/16 - REUMATOLOGIA, Delayed Diagnosis, Spondyloarthropathy, [SDV]Life Sciences [q-bio], MESH : Sacroiliac Joint, MESH: Epidemiologic Methods, Gastroenterology, Severity of Illness Index, MESH: Magnetic Resonance Imaging, 0302 clinical medicine, MESH : Back Pain, Back pain, Immunology and Allergy, MESH : Female, 030212 general & internal medicine, Age of Onset, MESH: Sacroiliac Joint, Axis, Cervical Vertebra, HLA-B27 Antigen, Sacroiliac joint, MESH : Prognosis, MESH: Middle Aged, MESH : Spondylarthritis, MESH : Adult, Middle Aged, Prognosis, Magnetic Resonance Imaging, 3. Good health, MESH : Age of Onset, [SDV] Life Sciences [q-bio], MESH : Phenotype, Cervical Vertebra, medicine.anatomical_structure, Phenotype, MESH: Young Adult, MESH : Severity of Illness Index, Female, medicine.symptom, Axis, musculoskeletal diseases, Adult, medicine.medical_specialty, MESH : Male, MESH: Age of Onset, MESH: Spondylarthritis, Immunology, MESH : Delayed Diagnosis, MESH : HLA-B27 Antigen, MESH : Young Adult, MESH: Phenotype, General Biochemistry, Genetics and Molecular Biology, MESH : Epidemiologic Methods, MESH: Prognosis, 03 medical and health sciences, Young Adult, Rheumatology, Internal medicine, MESH : Magnetic Resonance Imaging, MESH: Severity of Illness Index, Spondylarthritis, medicine, MESH : Sacroiliitis, Humans, MESH : Middle Aged, Sacroiliitis, MESH: Sacroiliitis, 030203 arthritis & rheumatology, Ankylosing spondylitis, HLA-B27, MESH: Humans, MESH : Axis, business.industry, MESH : Humans, MESH: Biological Markers, MESH: Adult, Sacroiliac Joint, medicine.disease, MESH: Male, Surgery, MESH : Biological Markers, MESH: Delayed Diagnosis, Back Pain, MESH: Back Pain, Age of onset, business, MESH: HLA-B27 Antigen, Epidemiologic Methods, MESH: Female, Biomarkers, MESH: Axis
Abstract: International audience; OBJECTIVE: To clarify the influence of human leucocyte antigen B27 (HLA-B27) status on the phenotype of early axial spondyloarthritis (SpA). METHODS: 708 patients with inflammatory back pain (IBP) defined by Calin or Berlin criteria were recruited; 654 fulfilled at least one of the SpA criteria (modified New York, European Spondyloarthropathy Study Group, Amor or Assessment of SpondyloArthritis international Society classification criteria for axial SpA) and were included in the analyses. Clinical, demographic and imaging parameters were compared between HLA-B27 positive and negative groups. Significant parameters in univariate differences between HLA-B27 positive and negative groups were retested in multivariate models explaining various outcomes. RESULTS: Patients had a short duration of axial symptoms (mean 1.5 years) and HLA-B27 was present in 61.5%. In multivariate analysis, HLA-B27 positivity was associated with a younger age at onset of IBP (regression coefficient (B)=(-2.60), p
Published: 2011
Full Text: View/download PDF

18. [Methodology of neuroepidemiological studies in tropical countries: a challenge?]

Author: Preux, Pierre-Marie, Ratsimbazafy, Voa, Bhalla, Devender, Ngoungou, Edgard Brice, Quet, Fabrice, Druet-Cabanac, Michel, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges (UNILIM), Service de Pharmacie Centrale [CHU Limoges], Département de Parasitologie, Mycologie et Médecine Tropicale, Faculté de Médecine-Université de Libreville, and Service de Santé au Travail [CHU Limoges]
Subjects: MESH: Humans, Data Collection, Tropical Medicine, Humans, MESH: Data Collection, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Nervous System Diseases, MESH: Epidemiologic Methods, Epidemiologic Methods, MESH: Developing Countries, MESH: Nervous System Diseases, MESH: Tropical Medicine, Developing Countries
Abstract: International audience; The purpose of this paper is to highlight the difficulties of applying neuroepidemiological methods in low income countries or developing countries, which are mostly tropical countries, taking advantage of the experience of the Institute of Neuroepidemiology and Tropical Neurology, which was created in Limoges in 1982. These difficulties could be related to several aspects: methodological, logistical, political or economical, linked to ethical issues, even difficulties to publish the studies. However, concept and neuroepidemiological methods should stay the same worldwide, even if their translation into practice could sometimes raise some problems in developing countries. Study protocol should be more detailed. Some specific epidemiological methods could be useful. Collection of data should be standardized. True cooperation at every level is needed for these researches to be valid.
Published: 2011
Full Text: View/download PDF

19. Impact of surgical site infection surveillance in a neurosurgical unit

Author: Laurent Riffaud, Sylvie Buffet-Bataillon, Gilles Brassier, Michel Cormier, Claire Haegelen, Martine Bonnaure-Mallet, Microbiologie : Risques Infectieux, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes]-Faculté de Chirurgie Dentaire de Rennes-Faculté d'Odontologie-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de neurochirurgie [Rennes] = Neurosurgery [Rennes], CHU Pontchaillou [Rennes], Brébion, Alice, Université de Rennes (UR)-CHU Pontchaillou [Rennes]-Faculté de Chirurgie Dentaire de Rennes-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-CHU Pontchaillou [Rennes]-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Université de Rennes - UFR d'Odontologie (UR Odontologie), and Université de Rennes (UR)-Université de Rennes (UR)
Subjects: medicine.medical_treatment, MESH: Epidemiologic Methods, Neurosurgical Procedures, Disease Outbreaks, MESH: Infection Control, 0302 clinical medicine, Hygiene, Deep brain stimulation, Infection control, 030212 general & internal medicine, MESH: Disease Outbreaks, media_common, MESH: Aged, Cross Infection, MESH: Middle Aged, Incidence (epidemiology), Surgical wound, General Medicine, Middle Aged, Antimicrobial, MESH: Hospitals, Hospitals, 3. Good health, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Sentinel Surveillance, Neurosurgery, Skin preparation, Surgical site infection, Adult, Microbiology (medical), MESH: Preoperative Care, medicine.medical_specialty, media_common.quotation_subject, 03 medical and health sciences, Internal medicine, Preoperative Care, MESH: Antibiotic Prophylaxis, medicine, Humans, Surgical Wound Infection, MESH: Surgical Wound Infection, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, Aged, Infection Control, MESH: Humans, business.industry, MESH: Cross Infection, MESH: Adult, MESH: Neurosurgical Procedures, Antibiotic Prophylaxis, Surgery, Epidemiologic Methods, business, Sentinel Surveillance, 030217 neurology & neurosurgery
Abstract: International audience; This article describes a two-year surveillance of neurosurgical site infections and an outbreak of infections in deep brain stimulation (DBS) cases. From April to December 2008, six patients had a DBS surgical site infection (SSI). Audits of hygiene practices, infection control of the healthcare environment, and preoperative antimicrobial prophylaxis characteristics were carried out. The results of surgical audits showed that skin preparation and antimicrobial prophylaxis were not being performed adequately. In 2008, the general SSI rate was 1.8% (27 SSIs/1471 patients). Length of preoperative stay was significantly longer among infected patients (2.7 ± 2.9 months) compared with uninfected patients (2.2 ± 4.6 months) (P=0.01). Based on these results, skin preparation and antimicrobial prophylaxis were reviewed with the neurosurgery team. In 2009, the general SSI rate was reduced to 1.1% (16 SSI in 1410 patients), a reduction from 2008 (P=0.12). Although the overall incidence of SSI in 2008 (1.8%) was within the range of published data, this surveillance of SSIs permitted identification of site operative infected patients surgically treated for DBS. A set of actions was then taken to reduce SSI risk. This work demonstrates how an active surveillance programme can successfully change clinical care practice.
Published: 2011
Full Text: View/download PDF

20. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

Author: D, Salmon-Ceron, F, Tubach, O, Lortholary, O, Chosidow, S, Bretagne, N, Nicolas, E, Cuillerier, B, Fautrel, C, Michelet, J, Morel, X, Puéchal, D, Wendling, M, Lemann, P, Ravaud, X, Mariette, Stéphane, Bretagne, Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Service de Dermatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Service de Rhumatologie [CH Le Mans], Centre Hospitalier Le Mans (CH Le Mans), Service de Rhumatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de gastro-entérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Régulation de la réponse immune, infection VIH-1 et autoimmunité, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), RATIO group, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri-Mondor, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Service de rhumatologie [CHU Pitié Salpêtrière] ( GRC-08 EEMOIS ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP), Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou, Centre Hospitalier du Mans, Hôpital Jean Minjoz, Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Épidémiologie et Évaluation des Maladies Ostéoarticulaires Inflammatoires et Systémiques (GRC-08 EEMOIS), Service des maladies infectieuses et réanimation médicale [Rennes], Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou
Subjects: Male, MESH: Antirheumatic Agents, Opportunistic infection, Anti-Inflammatory Agents, MESH : Aged, MESH: Epidemiologic Methods, Receptors, Tumor Necrosis Factor, Etanercept, MESH: Antibodies, Monoclonal, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Pneumocystosis, Immunology and Allergy, MESH : Female, 030212 general & internal medicine, MESH : Tumor Necrosis Factor-alpha, MESH: Aged, MESH: Immunoglobulin G, MESH: Middle Aged, MESH: Immunologic Factors, Antibodies, Monoclonal, Middle Aged, MESH : Adult, MESH : Antirheumatic Agents, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Antirheumatic Agents, Rheumatoid arthritis, MESH : Antibodies, Monoclonal, Female, France, medicine.drug, Adult, medicine.medical_specialty, MESH : Immunoglobulin G, MESH : Male, Immunology, Opportunistic Infections, MESH : Anti-Inflammatory Agents, Antibodies, Monoclonal, Humanized, MESH : Immunologic Factors, General Biochemistry, Genetics and Molecular Biology, MESH : Antibodies, Monoclonal, Humanized, MESH : Epidemiologic Methods, 03 medical and health sciences, Rheumatology, Psoriasis, Internal medicine, medicine, Adalimumab, Humans, Immunologic Factors, MESH : Middle Aged, Risk factor, MESH : France, Aged, 030203 arthritis & rheumatology, MESH: Humans, Tumor Necrosis Factor-alpha, business.industry, MESH : Humans, MESH : Opportunistic Infections, MESH: Adult, MESH: Opportunistic Infections, medicine.disease, MESH: Receptors, Tumor Necrosis Factor, Infliximab, MESH : Receptors, Tumor Necrosis Factor, MESH: Male, MESH: France, MESH: Antibodies, Monoclonal, Humanized, Immunoglobulin G, MESH: Tumor Necrosis Factor-alpha, MESH: Anti-Inflammatory Agents, Epidemiologic Methods, business, MESH: Female
Abstract: BackgroundAnti-tumour necrosis factor (TNF) therapy may be associated with opportunistic infections (OIs).ObjectiveTo describe the spectrum of non-tuberculosis OIs associated with anti-TNF therapy and identify their risk factors.MethodsA 3-year national French registry (RATIO) collected all cases of OI in patients receiving anti-TNF treatment for any indication in France. A case–control study was performed with three controls treated with anti-TNF agents per case, matched for gender and underlying inflammatory disease.Results45 cases were collected of non-TB OIs in 43 patients receiving infliximab (n=29), adalimumab (n=10) or etanercept (n=4) for rheumatoid arthritis (n=26), spondyloarthritides (n=3), inflammatory colitis (n=8), psoriasis (n=1) or other conditions (n=5). One-third (33%) of OIs were bacterial (4 listeriosis, 4 nocardiosis, 4 atypical mycobacteriosis, 3 non-typhoid salmonellosis), 40% were viral (8 severe herpes zoster, 3 varicella, 3 extensive herpes simplex, 4 disseminated cytomegalovirus infections), 22% were fungal (5 pneumocystosis, 3 invasive aspergillosis, 2 cryptococcosis) and 4% were parasitic (2 leishmaniasis). Ten patients (23%) required admission to the intensive care unit, and four patients (9%) died. Risk factors for OIs were treatment with infliximab (OR=17.6 (95% CI 4.3 - 72.9); p10 mg/day or intravenous boluses during the previous year (OR=6.3 (2.0 to 20.0); p=0.002).ConclusionVarious and severe OIs, especially those with intracellular micro-organisms, may develop in patients receiving anti-TNF treatment. Monoclonal anti-TNF antibody rather than soluble TNF receptor therapy and steroid use >10 mg/day are independently associated with OI.
Published: 2011
Full Text: View/download PDF

21. Return home at the end of life: Patients' vulnerability and risk factors

Author: P Le Coz, Y Matillon, François Chapuis, Christian Hervé, P Vassal, Service de soins palliatifs, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Laboratoire d'éthique médicale et médecine légale (LEM), Université Paris Descartes - Paris 5 (UPD5), Espace éthique méditerranéen, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Santé Individu Société (SIS), Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Méthodologie en Recherche Clinique, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL), Hôpital Bellevue, Santé Individu Société - SIS (SIS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2), Duchange, Nathalie, Université de Lyon-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'éthique médicale et médecine légale ( LEM ), Université Paris Descartes - Paris 5 ( UPD5 ), Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Santé Individu Société - SIS ( SIS ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Jean Monnet [Saint-Étienne] ( UJM ) -Hospices Civils de Lyon ( HCL ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Jean Moulin - Lyon III ( UJML ) -Université Lumière - Lyon 2 ( UL2 ), Université Claude Bernard Lyon 1 ( UCBL ), and Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL )
Subjects: Gerontology, Male, Palliative care, MESH : Caregivers, Vulnerability, MESH : Aged, MESH: Delivery of Health Care, MESH: Epidemiologic Methods, MESH : Attitude to Death, MESH : Patient Preference, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Risk Factors, MESH: Risk Factors, Epidemiology, Western world, MESH : Female, MESH: Residence Characteristics, MESH : Palliative Care, MESH: Terminally Ill, media_common, MESH: Patient Preference, Aged, 80 and over, MESH: Aged, Terminal Care, MESH: Middle Aged, Palliative Care, Patient Preference, General Medicine, MESH: Caregivers, MESH : Adult, Middle Aged, MESH : Risk Factors, Home Care Services, 3. Good health, MESH: Terminal Care, Caregivers, 030220 oncology & carcinogenesis, MESH : Residence Characteristics, [ SDV.ETH ] Life Sciences [q-bio]/Ethics, Female, MESH: Palliative Care, France, 0305 other medical science, End-of-life care, Autonomy, Adult, medicine.medical_specialty, Attitude to Death, Adolescent, media_common.quotation_subject, MESH : Male, MESH : Terminal Care, MESH: Home Care Services, Context (language use), Vulnerable Populations, MESH : Epidemiologic Methods, MESH : Terminally Ill, 03 medical and health sciences, 030502 gerontology, MESH: Attitude to Death, MESH : Adolescent, medicine, MESH : Vulnerable Populations, Humans, Terminally Ill, MESH : Middle Aged, Family, MESH : France, MESH : Aged, 80 and over, MESH: Family, Aged, MESH : Delivery of Health Care, MESH: Adolescent, MESH: Humans, business.industry, MESH : Home Care Services, MESH : Humans, MESH: Adult, [SDV.ETH] Life Sciences [q-bio]/Ethics, MESH: Male, MESH: Vulnerable Populations, [SDV.ETH]Life Sciences [q-bio]/Ethics, MESH: France, Anesthesiology and Pain Medicine, Observational study, MESH : Family, business, Epidemiologic Methods, Delivery of Health Care, MESH: Female
Abstract: International audience; Although most of the people in good health questioned about the subject said they would like to die at home, in the western world between 60 and 80% of deaths occur in hospital. Most authors consider that the indispensable conditions for a return home are the patient's desire and presence of the family and caregivers with the appropriate skills. The assessment of other factors predictive of a return home is inadequate. The aim of this study is to clarify how the return home is influenced by the vulnerability of the patient at the end of life, and by that of the family and caregivers. We carried out a multicentric, observational, prospective, exhaustive and longitudinal epidemiological study (three months follow-up), including 146 patients hospitalized at the end of their life and desiring to return home. For these patients the caregivers respected their freedom to choose to die at home in over half the cases (56%). Their overall vulnerability (personal, family context and caregivers) had a significant influence on the return home. This overall vulnerability was in fact identified as applying in 40% of the clinical situations, and made the possibility of a return home 50% less likely.
Published: 2011
Full Text: View/download PDF

22. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author: Robin, Marie, Tabrizi, Reza, Mohty, Mohamad, Furst, Sabine, Michallet, Mauricette, Bay, Jacques-Olivier, Cahn, Jean-Yves, De Coninck, Eric, Dhedin, Nathalie, Bernard, Marc, Rio, Bernard, Buzyn, Agnès, Huynh, Anne, Bilger, Karin, Bordigoni, Pierre, Contentin, Nathalie, Porcher, Raphaël, Socié, Gérard, Milpied, Noel, Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Unité de transplantation médullaire et laboratoire d'oncologie moléculaire, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER-UNICANCER, TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Hematology, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-CHU Grenoble, Laboratoire Hubert Curien [Saint Etienne] (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Département d'Hématologie et Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Unité de Transplantation Médullaire, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Hôpital d'enfants, Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Haematology, CHU Bordeaux [Bordeaux], Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers, Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), CRLCC Jean Perrin, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Hematology, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-CHU Grenoble, Laboratoire Hubert Curien [Saint Etienne] ( LHC ), Institut d'Optique Graduate School ( IOGS ) -Université Jean Monnet [Saint-Étienne] ( UJM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP), Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Toulouse III - Paul Sabatier ( UPS ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Hôpital d'enfants, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Hematology, and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]
Subjects: Male, Transplantation Conditioning, MESH : Recurrence, MESH : Transplantation Conditioning, MESH : Aged, Graft vs Host Disease, MESH: Epidemiologic Methods, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Recurrence, MESH : Female, MESH : Graft Survival, MESH: Transplantation Conditioning, MESH: Treatment Outcome, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Graft Survival, MESH : Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Middle Aged, MESH : Adult, Prognosis, Treatment Outcome, surgical procedures, operative, MESH: Young Adult, Histocompatibility, Splenectomy, Female, MESH: Primary Myelofibrosis, Adult, MESH: Graft Survival, MESH : Male, MESH : Young Adult, MESH: Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, MESH: Splenectomy, MESH : Epidemiologic Methods, MESH: Prognosis, Young Adult, MESH : Hematopoietic Stem Cell Transplantation, Humans, MESH : Middle Aged, MESH : Splenectomy, MESH: Hematopoietic Stem Cell Transplantation, Aged, MESH: Humans, MESH : Humans, MESH : Histocompatibility, MESH: Adult, MESH: Male, MESH: Recurrence, MESH: Histocompatibility, Primary Myelofibrosis, MESH : Primary Myelofibrosis, Epidemiologic Methods, MESH: Female
Abstract: International audience; Allogeneic haematopoietic stem-cell transplantation (HSCT) is the only curative treatment for myelofibrosis. We report an analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) registry including patients with myelofibrosis transplanted between 1997 and 2008. Potential risk factors affecting engraftment, non-relapse mortality (NRM), overall survival (OS) and progression-free survival (PFS) were analysed. One hundred and forty-seven patients, aged 20-68 (median 53) years, diagnosed with primary (53%) or secondary myelofibrosis underwent HSCT; 59% of patients were transplanted from a matched sibling donor. The conditioning regimen was myeloablative in 31% of patients. Ninety percent of the patients engrafted. Factors affecting favourably engraftment were splenectomy before HSCT, human leucocyte antigen (HLA) matched sibling donor, peripheral stem cell use as source of stem cells and absence of pre-transplant thrombocytopenia. Four-year OS, PFS and NRM survival were 39% (95%confidence interval [CI]: 31-50), 32% (95%CI: 24-43) and 39% (95%CI 30-48), respectively. Multivariate analysis indicated that HLA-identical sibling donor, chronic phase disease and splenectomy in men had favourable impact on OS.
Published: 2011
Full Text: View/download PDF

23. Switch to second-line ART in West African routine care: incidence and reasons for switching

Author: Cecilia Pizzocolo, Christine Katlama, Jordi Landier, Louis Pizarro, Yoann Madec, Alain Akonde, Ibrahim Haidara, Arnaud Fontanet, Mahamadou Drabo, Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Solidarité thérapeutique & initiatives contre le sida (SOLTHIS), Hôpital régional de Ségou [Mali], Auteur indépendant, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM), and HESAM Université (HESAM)-HESAM Université (HESAM)
Subjects: Male, Pediatrics, Health (social science), MESH: CD4 Lymphocyte Count, MESH: Treatment Failure, Human immunodeficiency virus (HIV), HIV Infections, 030312 virology, medicine.disease_cause, MESH: Epidemiologic Methods, MESH: Antiretroviral Therapy, Highly Active, 0302 clinical medicine, Second line, Antiretroviral Therapy, Highly Active, Treatment Failure, 030212 general & internal medicine, MESH: Anti-HIV Agents, Routine care, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, MESH: Middle Aged, Drug Substitution, Incidence (epidemiology), Treatment options, MESH: HIV Infections, Middle Aged, 3. Good health, West african, Female, Adult, medicine.medical_specialty, Adolescent, Social Psychology, Anti-HIV Agents, Person years, 03 medical and health sciences, medicine, Humans, MESH: Adolescent, MESH: Humans, business.industry, Public Health, Environmental and Occupational Health, MESH: Adult, Antiretroviral therapy, MESH: Male, MESH: Drug Substitution, CD4 Lymphocyte Count, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; In sub-Saharan Africa, while antiretroviral therapy (ART) becomes widely available, access to biological measurements to monitor patients under ART remains scarce, making the management of ART difficult. We described the management of switching to second-line ART where HIV care is provided mainly in secondary health-care structures, in the region of Segou, Mali. Of 865 patients, followed under ART for a median time of 15 months, 40 switched to second-line ART (3.3 switches/100 person years). Reason for switching was failure in 18 patients (after 21 months in median) and severe intolerance in 13 (after three months in median). Switching to second-line ART occurred earlier when motivated by intolerance than by failure. The low rate of switch compares well with other studies, but was low compared to the expected rate of failure, and may indicate that physicians are reluctant to switch ART when treatment options are limited.
Published: 2011
Full Text: View/download PDF

24. Prognostic value of the Geneva prediction rule in patients in whom pulmonary embolism is ruled out

Author: Bertoletti, L, Le Gal, G, Aujesky, D, Roy, P-M, Sanchez, Oliver Lope, Verschuren, F, Bounameaux, Henri, Perrier, Arnaud, Righini, Marc Philip, Service d'angiologie et d'hémostase (MR), Hôpital Universitaire de Genève, Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Division of General Internal Medicine (DGIM), Bern University Hospital, Service des Urgences (PMR), CHRU - ANGERS, Department of Pneumology and Intensive Care Unit (DPICU), Université Paris Descartes - Paris 5 (UPD5), Emergency Department (FV - ED), Saint Luc University Hospital, Department of Internal Medicine (AP), Geneva University Hospital (HUG), Université de Brest (UBO)-Université de Brest (UBO), Service d'angiologie et d'hémostase ( MR ), Groupe de recherche sur la thrombose ( GRT (EA 3065) ), Université Jean Monnet [Saint-Étienne] ( UJM ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Division of General Internal Medicine ( DGIM ), Service des Urgences ( PMR ), Department of Pneumology and Intensive Care Unit ( DPICU ), Université Paris Descartes - Paris 5 ( UPD5 ), Emergency Department ( FV - ED ), Department of Internal Medicine ( AP ), and Geneva University Hospital ( HUG )
Subjects: MESH: Pulmonary Embolism, Male, MESH : Aged, MESH: Epidemiologic Methods, France/epidemiology, Switzerland/epidemiology, MESH: Belgium, Belgium, Neoplasms, MESH : Cardiovascular Diseases, MESH : Female, MESH: Neoplasms, Cardiovascular Diseases/mortality, ddc:616, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, MESH : Adult, Middle Aged, Prognosis, Cardiovascular Diseases, MESH : Pulmonary Embolism, Female, Neoplasms/mortality, France, MESH : Belgium, Respiratory Insufficiency, MESH : Decision Support Techniques, Switzerland, Adult, MESH : Switzerland, Respiratory Insufficiency/mortality, MESH : Male, MESH: Switzerland, Patient Readmission, MESH : Epidemiologic Methods, MESH: Prognosis, Decision Support Techniques, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, MESH: Patient Readmission, Humans, Pulmonary Embolism/diagnosis, MESH : Middle Aged, MESH : France, Belgium/epidemiology, MESH : Patient Readmission, Aged, MESH: Humans, MESH : Humans, MESH: Cardiovascular Diseases, MESH: Decision Support Techniques, MESH: Adult, MESH : Respiratory Insufficiency, MESH : Neoplasms, MESH: Male, MESH: France, Patient Readmission/statistics & numerical data, Epidemiologic Methods, Pulmonary Embolism, MESH: Female, MESH: Respiratory Insufficiency, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; OBJECTIVES: The prognosis of patients in whom pulmonary embolism (PE) is suspected but ruled out is poorly understood. We evaluated whether the initial assessment of clinical probability of PE could help to predict the prognosis for these patients. DESIGN: Retrospective analysis of data obtained during a prospective multicentre management study. SETTING: Six general and teaching hospitals in Belgium, France and Switzerland. SUBJECTS: In 1334 patients in whom PE was ruled out, 3-month mortality data were available (hospital readmission status was unknown for three patients) and clinical probability was evaluated with the revised Geneva score (RGS). MAIN OUTCOME MEASURES: Three-month mortality and readmission rates. RESULTS: Three-month mortality and readmissions rates were 3% and 19%, respectively and differed significantly depending on the RGS-determined PE probability group (P
Published: 2011
Full Text: View/download PDF

25. Exposures in painting-related occupations and risk of lung cancer among men: results from two case-control studies in Montreal

Author: Agnihotram V. Ramanakumar, Lesley Richardson, Marie-Élise Parent, Jack Siemiatycki, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Division of Cancer Epidemiology, McGill University = Université McGill [Montréal, Canada], Institut Armand Frappier (INRS-IAF), Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP), and School of Public Health
Subjects: Adult, Male, MESH: Occupational Diseases, medicine.medical_specialty, MESH: Socioeconomic Factors, Lung Neoplasms, MESH: Quebec, Population, Context (language use), [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Paint, MESH: Epidemiologic Methods, MESH: Occupational Exposure, Occupational medicine, Environmental health, Occupational Exposure, Epidemiology, Paint, medicine, Humans, Risk factor, Occupations, Lung cancer, education, Aged, MESH: Aged, education.field_of_study, MESH: Occupations, MESH: Humans, MESH: Middle Aged, business.industry, Public Health, Environmental and Occupational Health, Quebec, Cancer, MESH: Adult, Middle Aged, medicine.disease, MESH: Male, Surgery, MESH: Lung Neoplasms, Occupational Diseases, Socioeconomic Factors, Relative risk, [SDV.TOX]Life Sciences [q-bio]/Toxicology, Female, business, Epidemiologic Methods, MESH: Female
Abstract: BackgroundEvidence that painters may be at risk for lung cancer comes mainly from analyses on job titles rather than on specific exposures found in the environments of painters.MethodsIn the context of two large population-based case–control studies of lung cancer carried out in Montreal, we were able to assess possible relationships between lung cancer and the occupation of painter as well as exposure to paints, varnishes and stains. Interviews for study I were conducted in 1979–1986 (857 cases, 533 population controls, 1349 cancer controls) and interviews for study II were conducted in 1996–2001 (765 cases and 899 controls). Detailed lifetime job histories were elicited; a team of hygienists and chemists evaluated the evidence of exposure to many occupational substances including paint-related substances. The relative risk of lung cancer was estimated, adjusting for several potential confounders, including smoking, in a three-variable parameterisation.ResultsIn analyses pooling the two studies, painters had an OR of lung cancer of 1.3 (95% CI 0.9 to 2.2). Regarding exposures, ORs were: for wood varnishes and stains, 1.6 (95% CI 1.0 to 2.3); for wood and gypsum paints, 1.3 (95% CI 0.9 to 1.7); and for metal coatings, 1.1 (95% CI 0.8 to 1.6). Small numbers hampered evaluation of dose–response relationships.ConclusionsWhile our results cannot exclude chance or residual confounding by smoking or concomitant occupational exposures, they provide further evidence that some exposures in paint-related occupations, most notably wood varnishes and stains, increase the risk of lung cancer.
Published: 2011
Full Text: View/download PDF

26. Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial

Author: Bernadette Kantelip, Harouna Zaki, Francine Arbez-Gindre, Mariette Mercier, Franck Monnien, Christophe Borg, Christiane Mougin, Jean-François Bosset, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Service d'oncologie Médicale, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Service d'Anatomie pathologique [CHRU Besançon], and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Male, Oncology, MESH: Neoplasm Proteins, Pathology, MESH: Combined Modality Therapy, Colorectal cancer, medicine.medical_treatment, MESH : Aged, medicine.disease_cause, MESH: Epidemiologic Methods, law.invention, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Phosphorylation, 0302 clinical medicine, MESH: Aged, 80 and over, Randomized controlled trial, law, MESH : Tumor Markers, Biological, MESH : STAT3 Transcription Factor, MESH : Female, Phosphorylation, MESH : Rectal Neoplasms, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, 0303 health sciences, MESH : Cell Nucleus, MESH: Middle Aged, MESH : Prognosis, MESH: STAT3 Transcription Factor, Anatomical pathology, MESH : Chemotherapy, Adjuvant, General Medicine, Middle Aged, MESH : Adult, Prognosis, Combined Modality Therapy, Neoplasm Proteins, 3. Good health, Treatment Outcome, Chemotherapy, Adjuvant, MESH: Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, France, Adult, STAT3 Transcription Factor, MESH: Cell Nucleus, medicine.medical_specialty, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, MESH: Prognosis, MESH : Epidemiologic Methods, Pathology and Forensic Medicine, 03 medical and health sciences, MESH : Neoplasm Proteins, Internal medicine, Biomarkers, Tumor, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH : France, Aged, 030304 developmental biology, Cell Nucleus, Chemotherapy, MESH: Humans, Oncogene, MESH: Phosphorylation, Rectal Neoplasms, business.industry, MESH : Humans, Cancer, MESH: Rectal Neoplasms, MESH: Adult, medicine.disease, MESH: Male, Clinical trial, MESH: France, MESH: Tumor Markers, Biological, Epidemiologic Methods, Carcinogenesis, business, MESH : Combined Modality Therapy, MESH: Female
Abstract: International audience; BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) has been implicated as an oncogene in several neoplastic diseases. However, the biological effects of STAT3 have not been extensively studied in rectal carcinogenesis. AIMS: To evaluate STAT3 activation in advanced rectal cancers and its association with clinicopathological variables and prognosis. METHODS: Nuclear immunohistochemical expression of phosphorylated STAT3 (p-STAT3) was studied in 104 advanced rectal cancers (T3-T4). All patients were participating in the EORTC 22921 trial to assess whether preoperative chemoradiotherapy followed by postoperative chemotherapy improved overall and progression-free survival. RESULTS: Nuclear p-STAT3 expression was detected in 37.5% of rectal cancer patients. No correlation was observed between p-STAT3 and any clinicopathological variables tested. However, patients with tumours positive for p-STAT3 had significantly improved overall survival. CONCLUSION: These results highlight an unexpected role for nuclear p-STAT3 expression in advanced rectal cancers and need further investigation to clarify this finding.
Published: 2010
Full Text: View/download PDF

27. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay

Author: Jean-Claude Daubert, Kim O'Connor, Julien Magne, Marie Moonen, Erwan Donal, Luc Pierard, Patrizio Lancellotti, Groupe Interdisciplinaire de Génoprotéomique Appliquée (GIGA-Research), Université de Liège, Service de cardiologie et maladies vasculaires, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], This study was conducted with the approval of the Liège CHU Sart Tilman and CHU de Ponchaillou, Rennes, FRANCE., Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], and CHU Pontchaillou [Rennes]
Subjects: Male, MESH: Echocardiography, Doppler, 030204 cardiovascular system & hematology, MESH: Epidemiologic Methods, Ventricular Function, Left, MESH: Ventricular Function, Left, 0302 clinical medicine, MESH: Aged, 80 and over, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Left atrial, Medicine, 030212 general & internal medicine, MESH: Aortic Valve Stenosis, Aged, 80 and over, Heart Valve Prosthesis Implantation, MESH: Aged, MESH: Middle Aged, MESH: Blood Flow Velocity, Middle Aged, Prognosis, Echocardiography, Doppler, 3. Good health, Aortic valve area, Aortic Valve, Risk stratification, Cardiology, cardiovascular system, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Radiology, medicine.symptom, Cardiology and Cardiovascular Medicine, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, Blood Flow Velocity, Moderate to severe, MESH: Heart Valve Prosthesis Implantation, medicine.medical_specialty, MESH: Hemodynamics, Asymptomatic, MESH: Prognosis, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Humans, Aged, MESH: Humans, business.industry, Hemodynamics, Aortic Valve Stenosis, medicine.disease, MESH: Male, Stenosis, Epidemiologic Methods, business, MESH: Aortic Valve, MESH: Female
Abstract: International audience; OBJECTIVE: We sought to evaluate prognostic markers of clinical outcome in asymptomatic patients with moderate to severe aortic stenosis (AS). DESIGN: Prospective follow-up of asymptomatic patients with moderate to severe AS. The patients underwent clinical and Doppler echocardiographic evaluation. SETTING: Department of Cardiology. PATIENTS: 163 patients with moderate to severe AS (aortic valve area < or =0.6 cm(2)/m(2)). MAIN OUTCOME MEASURES: Risk stratification. Predefined endpoints for assessing the outcome were the occurrence during follow-up of symptoms, aortic valve replacement or death. RESULTS: During follow-up (mean, 20 (19) months), 11 patients developed symptoms but were not operated on, 57 required aortic valve replacement and six patients died. In multivariable Cox regression analysis, four parameters that were associated with the outcome were identified: peak aortic jet velocity, left ventricular systolic (LV) longitudinal deformation, valvulo-arterial impedance and indexed left atrial area. Using receiver-operator characteristic curve analysis, a peak aortic jet velocity > or =4.4 m/s, a LV longitudinal myocardial deformation < or =15.9%, a valvular-arterial impedance > or =4.9 mm Hg/ml per m(2) and an indexed left atrial area > or =12.2 cm(2)/m(2) were identified as the best cut-off values to be associated with events. CONCLUSIONS: In asymptomatic patients with moderate to severe AS, measurements that integrate the ventricular, vascular and valvular components of the disease improve risk stratification.
Published: 2010
Full Text: View/download PDF

28. Estimating the number of alcohol-attributable deaths: methodological issues and illustration with French data for 2006

Author: Rey, Grégoire, Boniol, Mathieu, Jougla, Eric, Centre d'épidémiologie sur les causes médicales de décès (CépiDc), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre International de Recherche contre le Cancer - International Agency for Research on Cancer (CIRC - IARC), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), and Camelin, Laurence
Subjects: MESH: Adolescent, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: Chronic Disease, MESH: Adult, MESH: Epidemiologic Methods, MESH: Male, Alcohol-attributable mortality: methods, MESH: France, MESH: Commerce, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Young Adult, MESH: Neoplasms, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Data Interpretation, Statistical, MESH: Female, MESH: Alcohol Drinking, MESH: Alcoholic Beverages
Abstract: International audience; AIMS: Computing the number of alcohol-attributable deaths requires a series of hypotheses. Using French data for 2006, the potential biases are reviewed and the sensitivity of estimates to various hypotheses evaluated. METHODS: Self-reported alcohol consumption data were derived from large population-based surveys. The risks of occurrence of diseases associated with alcohol consumption and relative risks for all-cause mortality were obtained through literature searches. All-cause and cause-specific population alcohol-attributable fractions (PAAFs) were calculated. In order to account for potential under-reporting, the impact of adjustment on sales data was tested. The 2006 mortality data were restricted to people aged between 15 and 75 years. RESULTS: When alcohol consumption distribution was adjusted for sales data, the estimated number of alcohol-attributable deaths, the sum of the cause-specific estimates, was 20 255. Without adjustment, the estimate fell to 7158. Using an all-cause mortality approach, the adjusted number of alcohol-attributable deaths was 15 950, while the non-adjusted estimate was a negative number. Other methodological issues, such as computation based on risk estimates for all causes for 'all countries' or only 'European countries', also influenced the results, but to a lesser extent. DISCUSSION: The estimates of the number of alcohol-attributable deaths varied greatly, depending upon the hypothesis used. The most realistic and evidence-based estimate seems to be obtained by adjusting the consumption data for national alcohol sales, and by summing the cause-specific estimates. However, interpretation of the estimates must be cautious in view of their potentially large imprecision.
Published: 2010
Full Text: View/download PDF

29. ERS position paper: work-related respiratory diseases in the EU

Author: Sigsgaard, T., Nowak, D., Annesi-Maesano, I., Nemery, B., Toren, K., Viegi, G., Radon, K., Burge, S., Heederik, D., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Federal Office of Meteorology and Climatology MeteoSwiss, Institute for Atmospheric and Climate Science [Zürich] (IAC), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), G Nagel, G Weinmayr, Kleiner A, L-Marcos Garcia, DP Strachan, Phase Deux Groupe d'étude ISAAC ., Risk Assessment of Toxic and Immunomodulatory Agents, and Dep IRAS
Subjects: MESH: Asthma, MESH: Respiratory Sounds, MESH: Food Habits, MESH: Epidemiologic Methods, MESH: Dust, MESH: Occupational Exposure, 0302 clinical medicine, MESH: Child, Prevalence, 030212 general & internal medicine, Occupational lung disease, ComputingMilieux_MISCELLANEOUS, media_common, COPD, education.field_of_study, MESH: Middle Aged, MESH: Risk, Dust, Middle Aged, 3. Good health, Europe, Occupational Diseases, MESH: Seafood, MESH: Respiration Disorders, MESH: Fruit, Pulmonary and Respiratory Medicine, Risk, MESH: Occupational Diseases, medicine.medical_specialty, MESH: Hypersensitivity, Population, Occupational disease, Coronacrisis-Taverne, Air Pollutants, Occupational, Work related, MESH: Air Pollutants, Occupational, 03 medical and health sciences, MESH: Diet, MESH: Skin Tests, Environmental health, Occupational Exposure, medicine, media_common.cataloged_instance, Humans, European union, education, MESH: Prevalence, Asthma, MESH: Diet, Mediterranean, MESH: Humans, business.industry, MESH: Income, medicine.disease, Respiration Disorders, MESH: Vegetables, MESH: Male, 030228 respiratory system, Physical therapy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, business, MESH: Female
Abstract: According to a 2000 estimate based on workforce data and the CAREX (Carcinogen Exposure) database 1 there were 386,000 deaths worldwide due to non-cancer respiratory diseases (asthma: 38,000; chronic obstructive pulmonary disease (COPD): 318,000; pneumoconioses: 30,000) and nearly 6.6 million disability-adjusted life years (DALYs) (asthma: 1,621,000; COPD: 3,733,000; pneumoconioses: 1,288,000) attributable to occupational exposure to airborne particulates. The same figures for Europe were 52,700 deaths (asthma: 6,200; COPD: 39,300; pneumoconioses: 7,200) and 868,000 DALYs (asthma: 139,000; COPD: 468,000; pneumoconioses: 261,000). Respiratory diseases rank as the third most prevalent occupational disease category (after ergonomic and stress-related diseases) according to a survey of occupational diseases in the European Union (EU). The prevalence of respiratory diseases was 296 per 100,000 population, with the highest proportion found in the mining industry. This amounts to almost 600,000 persons in the former 15 member states. Many of these diseases, though induced while working, are chronic, thus explaining the highest prevalence among older workers (0.5% aged 55–64 yrs). Traditional high-risk occupations, such as mining, farming, manufacturing and service work ( e.g. hairdressers), are among the professions with a high prevalence of occupational lung diseases. However, high rates of occupational lung disease are also seen in newer professions, such as public administration, education 2 and occupational cleaning; the latter could be a reflection of problems related to new cleaning procedures, as found by the European Community Respiratory Health Survey (ECRHS) 3, or to problems with indoor air in public spaces. The pneumoconioses induced by exposure to mineral and other dusts at high concentrations were the dominating occupational lung diseases in the early industrialisation era. Their prevalence has been decreasing during the past decades. At the same time the obstructive lung diseases have gained increased importance, first because these diseases are widespread in the population, hence even small occupational contributions …
Published: 2010
Full Text: View/download PDF

30. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.: Lymphoma complicating anti-TNF therapy

Author: Mariette , Xavier, Tubach , Florence, Bagheri , Haleh, Bardet , Michel, Berthelot , Jean-Marie, Gaudin , Philippe, Heresbach , Denis, Martin , Antoine, Schaeverbeke , Thierry, Salmon , Dominique, Lemann , Marc, Hermine , Olivier, Raphael , Martine, Ravaud , Philippe, Service de rhumatologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Pharmacoépidémiologie : Evaluation de l'exposition et du risque médicamenteux, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], Service de médecine interne et rhumatologie, Centre Hospitalier Régional d'Orléans (CHRO)-Hôpital de la source, Service de Rhumatologie, Hôtel-Dieu, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes], Hôpital de St Brieuc, CHU Bordeaux [Bordeaux], Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de gastro-entérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Laboratoire d'Hématologie, Centre Hospitalier Régional d'Orléans (CHR)-Hôpital de la source, Service d'hépato-gastro-entérologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Toulouse III - Paul Sabatier ( UPS ), Centre Hospitalier Régional d'Orléans ( CHR ) -Hôpital de la source, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-Hôpital Michallon, Service de Gastroentérologie, Hôpital Pontchaillou, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP]
Subjects: MESH: Antirheumatic Agents, Lymphoma, MESH: Registries, MESH : Male, MESH : Aged, MESH: Arthritis, MESH: Epidemiologic Methods, MESH : Lymphoma, MESH : Epidemiologic Methods, Anti-TNF, immune system diseases, hemic and lymphatic diseases, MESH: Immunocompromised Host, MESH : Middle Aged, MESH : Female, Rheumatoid arthritis, MESH : France, MESH : Immunosuppressive Agents, MESH : Tumor Necrosis Factor-alpha, MESH: Aged, MESH: Middle Aged, MESH: Humans, MESH : Humans, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Arthritis, MESH : Immunocompromised Host, MESH : Antirheumatic Agents, MESH: Male, MESH: France, MESH: Tumor Necrosis Factor-alpha, Spondylarthropathies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Immunosuppressive Agents, Safety, MESH: Lymphoma, MESH: Female, MESH : Registries
Abstract: International audience; OBJECTIVE: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. METHODS: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case-control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. RESULTS: 38 cases of lymphoma, 31 non-Hodgkin's lymphoma (NHL) (26 B cell and five T cell), five Hodgkin's lymphoma (HL) and two Hodgkin's-like lymphoma were collected. Epstein-Barr virus was detected in both of two Hodgkin's-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3-7.1) and 3.6 (2.3-5.6) versus 0.9 (0.4-1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case-control study: odds ratio 4.7 (1.3-17.7) and 4.1 (1.4-12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2). CONCLUSION: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Published: 2010
Full Text: View/download PDF

31. Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3-arm anti-malarial drug trial in Cameroon

Author: Henri Gwet, Solange Youdom Whegang, Leonardo K. Basco, Jean-Christophe Thalabard, Mathématiques Appliquées à Paris 5 ( MAP5 - UMR 8145 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National des Sciences Mathématiques et de leurs Interactions-Centre National de la Recherche Scientifique ( CNRS ), Mathématiques Appliquées Paris 5 (MAP5 - UMR 8145), and Université Paris Descartes - Paris 5 (UPD5)-Institut National des Sciences Mathématiques et de leurs Interactions (INSMI)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Epidemiology, MESH : Child, Preschool, MESH: Epidemiologic Methods, MESH : Randomized Controlled Trials as Topic, MESH: Regression Analysis, MESH : Multicenter Studies as Topic, MESH : Malaria, Falciparum, law.invention, MESH: Proportional Hazards Models, Randomized controlled trial, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, law, MESH : Regression Analysis, Multicenter Studies as Topic, Cameroon, Malaria, Falciparum, MESH: Treatment Outcome, Randomized Controlled Trials as Topic, lcsh:R5-920, [STAT.AP]Statistics [stat]/Applications [stat.AP], MESH: Malaria, Falciparum, Hazard ratio, MESH : Models, Statistical, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Infant, Drug Combinations, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Pyrimethamine, Treatment Outcome, MESH : Drug Combinations, Child, Preschool, Regression Analysis, Drug Therapy, Combination, lcsh:Medicine (General), Research Article, medicine.drug, medicine.medical_specialty, MESH: Pyrimethamine, Coverage probability, Health Informatics, Amodiaquine, MESH : Treatment Outcome, Ordinal regression, MESH : Amodiaquine, MESH : Sulfadoxine, MESH : Epidemiologic Methods, Antimalarials, Internal medicine, Sulfadoxine, medicine, Humans, MESH : Pyrimethamine, MESH: Amodiaquine, Proportional Hazards Models, MESH: Drug Combinations, MESH: Humans, Models, Statistical, MESH : Cameroon, Proportional hazards model, business.industry, MESH : Drug Therapy, Combination, MESH: Child, Preschool, MESH : Humans, [ STAT.AP ] Statistics [stat]/Applications [stat.AP], Infant, Odds ratio, MESH: Cameroon, MESH : Proportional Hazards Models, MESH: Antimalarials, Confidence interval, Surgery, MESH: Drug Therapy, Combination, MESH: Randomized Controlled Trials as Topic, MESH: Multicenter Studies as Topic, MESH : Antimalarials, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Epidemiologic Methods, business, MESH: Models, Statistical, MESH: Sulfadoxine
Abstract: Background Malaria remains a burden in Sub-Saharan Countries. The strategy proposed by the World Health Organization (WHO) is to systematically compare the therapeutic efficacy of antimalarial drugs using as primary outcome for efficacy, a four-category ordered criterion. The objective of the present work was to analyze the treatment effects on this primary outcome taking into account both a center-effect and individual covariates. A three-arm, three-centre trial of Amodiaquine (AQ), sulfadoxine-pyrimethamine (SP) and their combination (AQ + SP), conducted by OCEAC-IRD in 2003, in 538 children with uncomplicated Plasmodium falciparum malaria, is used as an illustration. Methods Analyses were based on ordinal regression methods, assuming an underlying continuous latent variable, using either the proportional odds (PO) or the proportional hazards (PH) models. Different algorithms, corresponding to both frequentist- and bayesian-approaches, were implemented using the freely available softwares R and Winbugs, respectively. The performances of the different methods were evaluated on a simulated data set, and then they were applied on the trial data set. Results Good coverage probability and type-1 error for the treatment effect were achieved. When the methods were applied on the trial data set, results highlighted a significance decrease of SP efficacy when compared to AQ (PO, odds ratio [OR] 0.14, 95% confidence interval [CI] 0.04-0.57; hazard ratio [HR] 0.605, 95% CI 0.42-0.82), and an equal effectiveness between AQ + SP and AQ (PO, odds ratio [OR] 1.70, 95% confidence interval [CI] 0.25-11.44; hazard ratio [HR] 1.40, 95% CI 0.88-2.18). The body temperature was significantly related to the responses. The patient weights were marginally associated to the clinical response. Conclusion The proposed analyses, based on usual statistical packages, appeared adapted to take into account the full information contained in the four categorical outcome in malaria trials, as defined by WHO, with the possibility of adjusting on individual and global covariates.
Published: 2010
Full Text: View/download PDF

32. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry.: Lymphoma complicating anti-TNF therapy

Author: Mariette, Xavier, Tubach, Florence, Bagheri, Haleh, Bardet, Michel, Berthelot, Jean-Marie, Gaudin, Philippe, Heresbach, Denis, Martin, Antoine, Schaeverbeke, Thierry, Salmon, Dominique, Lemann, Marc, Hermine, Olivier, Raphael, Martine, Ravaud, Philippe, Gillet, Catherine, Service de rhumatologie, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Pharmacoépidémiologie [CHU Toulouse], Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service de médecine interne et rhumatologie, Centre Hospitalier Régional d'Orléans (CHRO)-Hôpital de la source, Service de Rhumatologie, Hôtel-Dieu, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service d'hépato-gastro-entérologie [Rennes] = Gastroenterology [Rennes], CHU Pontchaillou [Rennes], Hôpital de St Brieuc, CHU Bordeaux [Bordeaux], Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de gastro-entérologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], and Laboratoire d'Hématologie
Subjects: MESH: Aged, MESH: Antirheumatic Agents, MESH: Middle Aged, MESH: Humans, Lymphoma, MESH: Registries, MESH: Arthritis, MESH: Epidemiologic Methods, MESH: Male, Anti-TNF, MESH: France, immune system diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, hemic and lymphatic diseases, MESH: Tumor Necrosis Factor-alpha, MESH: Immunocompromised Host, Spondylarthropathies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Immunosuppressive Agents, Safety, Rheumatoid arthritis, MESH: Lymphoma, MESH: Female
Abstract: International audience; OBJECTIVE: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. METHODS: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case-control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. RESULTS: 38 cases of lymphoma, 31 non-Hodgkin's lymphoma (NHL) (26 B cell and five T cell), five Hodgkin's lymphoma (HL) and two Hodgkin's-like lymphoma were collected. Epstein-Barr virus was detected in both of two Hodgkin's-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3-7.1) and 3.6 (2.3-5.6) versus 0.9 (0.4-1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case-control study: odds ratio 4.7 (1.3-17.7) and 4.1 (1.4-12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2). CONCLUSION: The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.
Published: 2010
Full Text: View/download PDF

33. Validation of the use of historical events to estimate the age of subjects aged 65 years and over in Cotonou (Benin)

Author: Benoît Marin, Pierre-Marie Preux, Victoire Agueh, Philippe Nubukpo, Moussiliou Noël Paraïso, Maëlenn Guerchet, Dismand Houinato, Neuroépidémiologie Tropicale et Comparée (NETEC), Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Université de Limoges (UNILIM), Unité d'Enseignement et de Recherche de Neurologie, Faculté des sciences de la santé-University of Abomey Calavi (UAC), Centre de Mémoire de Ressources et de Recherches [Limoges] (CMRR Limoges), CHU Limoges-CH Esquirol [Limoges] (CH Esquirol), Hôpital Psychiatrique La Valette, Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, and Université de Limoges (UNILIM)
Subjects: Male, medicine.medical_specialty, Epidemiology, Cross-sectional study, MESH: Epidemiologic Methods, 03 medical and health sciences, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Benin, MESH: Cross-Sectional Studies, Age groups, medicine, Benin, Humans, 030212 general & internal medicine, Date of birth, Aged, Aged, 80 and over, MESH: Aged, MESH: Humans, business.industry, History, 20th Century, MESH: Male, Cross-Sectional Studies, Female, MESH: History, 20th Century, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Epidemiologic Methods, business, MESH: Female, 030217 neurology & neurosurgery, Demography
Abstract: Background: Our aim was to validate the use of historical events as tools for estimating the age of people ≧65 years in Cotonou (Benin). Methods: The survey was conducted in Cotonou, the economic capital of Benin. We included people aged ≧65 years, with at least a primary education level and an administrative document certifying their date of birth. The historical events were the solar eclipse of 1946 covering the national territory and the date of independence (1st August 1960) of Dahomey (Benin). Agreement between estimated and actual age was assessed by the intraclass correlation coefficient and the Bland and Altman graphical representation. Results: We included 112 subjects. The intraclass correlation coefficient between actual and estimated age by the use of historical landmarks was 0.87 (95% CI = 0.81–0.91), i.e. an excellent concordance. The graph of Bland and Altman did not demonstrate any systematic error of estimation. Conclusion: The development of similar tools in other parts of Africa and developing countries may improve the quality of information collected in epidemiological studies and thereby enhance the accuracy of the results of studies conducted on age-related disorders such as dementia.
Published: 2010
Full Text: View/download PDF

34. Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort

Author: Fautrel , Bruno, Benhamou , Mathilde, Foltz , Violaine, Rincheval , Nathalie, Rat , Anne-Christine, Combe , Bernard, Berenbaum , Francis, Bourgeois , Pierre, Guillemin , Francis, Saraux , Alain, Rhumatologie, Université Paris Diderot - Paris 7 ( UPD7 ), Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Centre de coordination, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Nancy, Cancéropôle du Grand Est-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, CHRU Brest - Service de Rhumatologie ( CHU - BREST - Rhumato ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Centre d'Investigation Clinique ( CIC - Brest ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Cancéropôle du Grand Est-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Maladies chroniques, santé perçue, et processus d'adaptation ( APEMAC ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Montpellier ( UM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institute of Biomedical Engineering, École Polytechnique de Montréal (EPM), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Service de Rhumatologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Sorbonne Université - Faculté de Médecine - École de sages-femmes Saint-Antoine (SU ESF), Sorbonne Université (SU), Station de Technologie des Produits Végétaux (URTPV), Institut National de la Recherche Agronomique (INRA), Université de Lorraine (UL), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Université Montpellier 1 - UFR de Médecine (UM1 Médecine), Université Montpellier 1 (UM1), Hôpital Lapeyronie [Montpellier] (CHU), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and CHU Pitié-Salpêtrière [AP-HP]
Subjects: Male, Multivariate analysis, Time Factors, MESH : Aged, MESH: Epidemiologic Methods, MESH : Referral and Consultation, MESH : Early Diagnosis, MESH : Guideline Adherence, Arthritis, Rheumatoid, 0302 clinical medicine, MESH: Practice Guidelines as Topic, MESH: Early Diagnosis, Pharmacology (medical), MESH : Female, 030212 general & internal medicine, MESH: Quality of Health Care, Disease management (health), skin and connective tissue diseases, Referral and Consultation, ComputingMilieux_MISCELLANEOUS, MESH: Aged, MESH: Arthritis, Rheumatoid, MESH: Middle Aged, MESH : Quality of Health Care, Middle Aged, MESH : Adult, 3. Good health, MESH : Practice Guidelines as Topic, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Young Adult, Rheumatoid arthritis, Cohort, MESH: Guideline Adherence, Practice Guidelines as Topic, Female, MESH: Clinical Competence, Clinical Competence, France, Guideline Adherence, Health Services Research, Family Practice, MESH: Health Services Research, MESH : Time Factors, Adult, musculoskeletal diseases, medicine.medical_specialty, Referral, Adolescent, MESH : Family Practice, MESH : Male, MESH : Health Services Research, MESH : Young Adult, MESH : Epidemiologic Methods, 03 medical and health sciences, MESH: Referral and Consultation, Young Adult, Rheumatology, Internal medicine, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, medicine, Humans, MESH : Middle Aged, MESH : France, MESH: Family Practice, Aged, Quality of Health Care, 030203 arthritis & rheumatology, MESH: Adolescent, MESH: Humans, business.industry, MESH: Time Factors, MESH : Humans, MESH: Adult, medicine.disease, MESH : Clinical Competence, MESH: Male, MESH: France, Early Diagnosis, MESH : Arthritis, Rheumatoid, Physical therapy, Managed care, business, Epidemiologic Methods, MESH: Female, Rheumatism, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; OBJECTIVE: To assess the time to access a rheumatologist (TTAR) by early arthritis (EA) patients participating in a nationwide incidental cohort (ESPOIR) and compare it with European League Against Rheumatism (EULAR) recommendations, which recommends rapid referral, ideally within 6 weeks, to a rheumatologist for patients presenting with EA. METHODS: Eight hundred and thirteen patients with EA were included in the cohort between 2002 and 2005. The inclusion criteria were 18-70 years old, two or more swollen joints, symptom duration from 6 weeks to 6 months and possible RA diagnosis. TTAR was defined as the time between the first synovitis and first visit to a rheumatologist. TTAR and satisfaction of the EULAR guidelines were investigated by multiple linear and logistic regressions. RESULTS: Mean TTAR was 76 days; only 46.2% of patients were seen by a rheumatologist within the EULAR-recommended time frame. Patients' patterns of accessing medical care substantially affected access to specialized care: mean TTAR was 58 days for patients who directly scheduled an appointment with the rheumatologist and 78 days for those referred by their general practitioner (P < 0.0007). Only 57.2 and 44.5%, respectively, were able to consult a rheumatologist within 6 weeks. Multivariate analysis confirmed the significant impact of indirect access on TTAR, after adjustment for EA characteristics and medical density in the region. CONCLUSIONS: Significant disparities were identified in the care of EA patients in terms of early access to a rheumatologist. More effort is needed to optimize the physicians' knowledge about EA and to improve the efficiency of medical networks.
Published: 2010
Full Text: View/download PDF

35. [The case series method]

Author: Hocine, Mounia, Chavance, Michel, Escolano, Sylvie, Chaire d'Hygiène et sécurité du travail, Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: transient exposures, self-control, vaccination Série de cas, événement à survenue aigüe, vaccination, MESH: Epidemiologic Methods, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, auto-appariement, MESH: Statistical Distributions, Epidemiologic Methods, Case series, exposition intermittente, Statistical Distributions, acute event
Abstract: International audience; The case series method was developed by Farrington (1995) to investigate the strength of association between a time-varying exposure and an acute rare potentially recurrent event, using cases only. It can be used when the exposure can only be causally related to the event during a limited period of time. It has been widely used in pharmaco-epidemiology, particularly in the study of vaccine safety. The method is derived from a Poisson model by conditioning on the individual total number of events and its exposure history. As a consequence of this conditioning, the effects of fixed covariates cancel out, so that the method has a particular advantage as compared with cohort and case-control studies.
Published: 2010
Full Text: View/download PDF

36. Survival of patients with nonmetastatic pT3 renal tumours: a matched comparison of laparoscopic vs open radical nephrectomy

Author: Laurent Zini, Alexandre de La Taille, Jean-Jacques Patard, Maxime Crepel, Karim Bensalah, Pierre I. Karakiewicz, Vincenzo Ficarra, Andrea Manunta, Luca Cindolo, Herve Lang, Laurent Salomon, Didier Jacqmin, Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'urologie, CHU Strasbourg, Department of Urology, Université de Montréal (UdeM), Università degli studi di Verona = University of Verona (UNIVR), University of Verona (UNIVR), and De Villemeur, Hervé
Subjects: Nephrology, Male, medicine.medical_treatment, MESH: Laparoscopy, 030232 urology & nephrology, MESH: Epidemiologic Methods, Nephrectomy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, 0302 clinical medicine, MESH: Treatment Outcome, MESH: Aged, education.field_of_study, Univariate analysis, MESH: Middle Aged, MESH: Carcinoma, Renal Cell, Middle Aged, Kidney Neoplasms, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Renal vein, radical nephrectomy, medicine.medical_specialty, renal cell carcinoma, Urology, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Adipose capsule of kidney, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, education, Carcinoma, Renal Cell, Aged, MESH: Humans, business.industry, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, Surgery, MESH: Nephrectomy, Laparoscopy, MESH: Kidney Neoplasms, business, Epidemiologic Methods, Kidney cancer, MESH: Female, Kidney disease
Abstract: International audience; OBJECTIVES: To compare the oncological outcome of patients with pT3 renal tumours treated either by laparoscopic radical nephrectomy (LRN) or open RN (ORN). PATIENTS AND METHODS: In a retrospective review of a multi-institutional database, we identified 1003 patients with a T3N0M0 renal tumour and with no vena caval invasion. Sixty-five patients treated by LRN were matched with up to four patients treated by ORN. Exact matches were made for age, gender, tumour size, perirenal fat invasion, renal vein invasion, and histological subtype. Following the matching process there were 44 patients treated by LRN and 135 by ORN. Qualitative and continuous variables were compared using chi-square and independent-sample t-tests, respectively. Differences in survival were compared using the Kaplan-Meier method. A Cox regression model was used to test the effect of variables on survival. RESULTS: The two groups were comparable for age (P = 0.4), gender, tumour size (P = 0.4), tumour grade (P = 0.25) and histological subtype (P = 0.45). The mean follow-up was longer in the ORN group (55 vs 28 months, P < 0.001). There was no difference in survival between the ORN and LRN groups in the whole T3 population (P = 0.7), in those with perirenal fat invasion (P = 0.9), or in the subset with renal vein invasion (P = 0.31). In univariate analysis, the only predictor for death from cancer was tumour grade (P = 0.05). In multivariate analysis, no variable was significantly associated with cancer survival. CONCLUSIONS: LRN has no adverse effect on cancer survival compared to ORN in patients with microscopic T3 renal cancer. Additional prospective evaluation is warranted.
Published: 2009
Full Text: View/download PDF

37. Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer

Author: Ploussard, Guillaume, Salomon, Laurent, Allory, Yves, Terry, Stéphane, Vordos, Dimitri, Hoznek, Andreas, Abbou, Claude-Clément, Vacherot, Francis, De La Taille, Alexandre, INSERM U955, équipe 7, Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de pathologie [Mondor], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and Guellaen, Georges
Subjects: Adult, Male, high risk, MESH: Epidemiologic Methods, MESH: Prostate, MESH: Prostatectomy, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, biochemical recurrence, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Treatment Outcome, Aged, MESH: Aged, Prostatectomy, MESH: Humans, MESH: Middle Aged, Prostate, Prostatic Neoplasms, MESH: Adult, Middle Aged, Prostate-Specific Antigen, prostate cancer, radical prostatectomy, MESH: Male, MESH: Prostate-Specific Antigen, Treatment Outcome, MESH: Prostatic Neoplasms, Neoplasm Recurrence, Local, Epidemiologic Methods, MESH: Neoplasm Recurrence, Local
Abstract: International audience; STUDY TYPE: Therapy (case series) Level of Evidence 4. OBJECTIVE: To review the biochemical recurrence-free survival (RFS) rates of laparoscopic radical prostatectomy (LRP) in patients with a high risk of disease progression as defined by preoperative criteria of D'Amico et al. PATIENTS AND METHODS: Between October 2000 and May 2008, 110 patients had extraperitoneal LRP and bilateral pelvic lymph node sampling for high-risk prostate cancer in our department. High-risk prostate cancer was defined as a prostate-specific antigen (PSA) level of >20 ng/mL, and/or a biopsy Gleason score >or=8, and/or a clinical stage of T2c-T4 stage. The median follow-up was 37.6 months. Risk factors for time to biochemical recurrence were tested using log-rank survivorship analysis and Cox proportional hazards regression. RESULTS: Prostate cancer was organ-confined in 36% of patients; the Overall RFS was 79.4% and 69.8% at 1 and 3 years, respectively. The 3-year RFS rates for organ-confined cancer vs extracapsular extension were 100% and 54.3%, respectively (P < 0.001). The 3-year RFS rates for tumour-free seminal vesicle vs seminal vesicle invasion were 81.8% and 33.6%, respectively (P < 0.001). The 3-year RFS rates for negative surgical margins vs positive were 85.2% and 47.3%, respectively (P = 0.001). Compared with men with any single pathological risk factor or any two risk factors, men with all three risk factors had a significantly shorter time to PSA failure after LRP (log-rank test, P < 0.001). CONCLUSION: Among patients at increased risk of disease progression as defined by preoperative criteria, a third of men with organ-confined disease have a favourable prognosis. Men at high risk for early PSA failure could be better identified by pathological assessment of RP specimens, and selected for phase III randomized trials investigating adjuvant systemic treatment.
Published: 2009
Full Text: View/download PDF

38. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

Author: Marin, Benoît, Thiébaut, Rodolphe, Bucher, Heiner, Rondeau, Virginie, Costagliola, Dominique, Dorrucci, Maria, Hamouda, Osamah, Prins, Maria, Walker, A. Sarah, Porter, Kholoud, Sabin, Caroline, Chêne, Geneviève, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Basel Institute for Clinical Epidemiology, University Hospital Basel [Basel], Epidémiologie Clinique et Traitement de l'Infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento di Malattie Infettive, Reparto di Epidemiologia, Istituto Superiore di Sanita [Rome], Department of Infectious Disease Epidemiology, Robert Koch Institute [Berlin] (RKI), Cluster Infectious Diseases, Amsterdam BioMed Cluster, Medical Research Council Clinical Trials Unit (MRC CTU), University College of London [London] (UCL), Research Department of Infection and Population Health [London], and CASCADE has been funded through grants from the European Union BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708 and LSHP-CT-2006-018949.
Subjects: MESH: Immune Tolerance, MESH: Liver Diseases, MESH: CD4 Lymphocyte Count, CD4 cell count, MESH: Epidemiologic Methods, MESH: Antiretroviral Therapy, Highly Active, Hepatitis, MESH: Neoplasms, Causes of death, highly active, MESH: Acquired Immunodeficiency Syndrome, MESH: Adolescent, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: AIDS-Related Opportunistic Infections, MESH: Cardiovascular Diseases, MESH: Adult, Human Immunodeficiency Virus/AIDS, MESH: Male, Antiretroviral therapy, MESH: Young Adult, Neoplasm, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Bacterial infection, MESH: Female
Abstract: International audience; OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). DESIGN: Observational multicentre cohorts. METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification. RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.
Published: 2009
Full Text: View/download PDF

39. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study

Author: Vincent Cloutier, Pierre I. Karakiewicz, Elie Antebi, Francesco Montorsi, Shahrokh F. Shariat, Claudio Jeldres, Jean Jacques Patard, Laurent Zini, Hendrik Isbarn, Paul Perrotte, Umberto Capitanio, Department of urology, Università Vita-Salute San Raffaele, Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Cancer Prognostics and Health Outcomes Unit, Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), De Villemeur, Hervé, Capitanio, Umberto, Cloutier, Vincent, Zini, Laurent, Isbarn, Hendrik, Jeldres, Claudio, Shariat Shahrokh, F., Perrotte, Paul, Antebi, Elie, Patard Jean, Jacque, Montorsi, Francesco, and Karakiewicz Pierre, I.
Subjects: Oncology, Male, Pathology, MESH: Carcinoma, Papillary, medicine.medical_treatment, 030232 urology & nephrology, Chromophobe cell, MESH: Epidemiologic Methods, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Cause of Death, 0302 clinical medicine, MESH: Aged, 80 and over, Renal cell carcinoma, Cause of Death, MESH: Child, Child, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, MESH: Neoplasm Staging, MESH: Carcinoma, Renal Cell, Middle Aged, Prognosis, Nephrectomy, Kidney Neoplasms, 3. Good health, MESH: Young Adult, 030220 oncology & carcinogenesis, Child, Preschool, Female, Adult, medicine.medical_specialty, Adolescent, Urology, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Young Adult, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Carcinoma, Humans, education, Carcinoma, Renal Cell, Aged, Neoplasm Staging, MESH: Adolescent, MESH: Humans, Proportional hazards model, business.industry, MESH: Child, Preschool, MESH: Adult, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Carcinoma, Papillary, MESH: Male, MESH: Kidney Neoplasms, business, Epidemiologic Methods, Kidney cancer, MESH: Female, Clear cell
Abstract: International audience; OBJECTIVE To assess the magnitude of the effect of histological subtype (HS, the three most common being clear cell, papillary and chromophobe) on cause-specific mortality (CSM) from renal cell carcinoma (RCC). PATIENTS AND METHODS Univariable and multivariable Cox regression models included data from 11 618 patients treated with nephrectomy between 1988 and 2004 in nine Surveillance Epidemiology and End Results registries. We tested whether HS represents an independent predictor of CSM, and whether HS adds to the ability of other variables to predict CSM. The covariates comprised age, year of surgery, T stage, nodal status, M stage and Fuhrman grade. RESULTS In a multivariable model predicting CSM, HS was an independent predictor (P = 0.03), but failed to improve the accuracy of the model (+0.1% gain when HS was included in the model). CONCLUSION Although we confirmed that HS is an independent predictor for CSM, there was no gain in accuracy when HS was added to standard predictors of CSM. From a practical perspective, this implies that patients with clear cell, papillary and chromophobe HS share similar natural histories after nephrectomy, provided that other cancer characteristics are accounted for. From a statistical perspective, in multivariable models of CSM, the clear cell, papillary and chromophobe HS might be included as a single entity.
Published: 2009
Full Text: View/download PDF

40. Geographic life environments and coronary heart disease: a literature review, theoretical contributions, methodological updates, and a research agenda

Author: Basile Chaix, ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Chauvin, Pierre
Subjects: social-cognitive theories, MESH: Geography, eco-epidemiology, MESH: Environmental Exposure, Coronary Disease, Social Environment, MESH: Epidemiologic Methods, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Humans, 030212 general & internal medicine, Life Style, Social influence, neighborhood, MESH: Social Environment, 030505 public health, MESH: Humans, Geography, Operational definition, MESH: Sociology, Medical, Public Health, Environmental and Occupational Health, Social environment, MESH: Life Style, Environmental Exposure, General Medicine, Environmental exposure, Social relation, Context analysis, contextual analysis, MESH: Research, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Research Design, Sociology, Medical, social interactions, Observational study, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Coronary Disease, Epidemiologic Methods, 0305 other medical science, Social cognitive theory, Cognitive psychology
Abstract: International audience; A growing literature investigates associations between neighborhood social environments and coronary heart disease (CHD). After reviewing the literature, we present a theoretical model of the mechanisms through which geographic life environments may influence CHD, focusing particularly on the social-interactional environment. We suggest that, in addition to the common notions of social cohesion or fragmentation and social disorder, eco-epidemiologists should consider neighborhood identities and stigmatization processes. We posit that neighborhood social interactions affect the wide set of affective, cognitive, and relational experiences individuals have in their neighborhoods, which in turn influence the psycho-cognitive antecedents of behavior and in the end shape health behavior. Finally, we discuss key methodological challenges relevant to the advent of a new generation of neighborhood studies, including the operational definition of neighborhoods, non-residential environments, ecometric measurement, model specification strategies, mediational models, selection processes and notions of empirical/structural confounding, and the relevance of observational versus interventional studies.
Published: 2009

41. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis

Author: De Angelis, Roberta, Francisci, Silvia, Baili, Paolo, Marchesi, Francesca, Roazzi, Paolo, Belot, Aurã©lien, Crocetti, Emanuele, Pury, Pierre, Knijn, Arnold, Coleman, Michel, Capocaccia, Riccardo, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Cancer Research, MESH: Quality Control, computer.software_genre, MESH: Epidemiologic Methods, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Medicine, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, education.field_of_study, Database, Relative survival, Incidence (epidemiology), Europe, Population registries, Survival analysis, Vital statistics, Databases as Topic, Epidemiologic Methods, Humans, Quality Control, Oncology, MESH : Quality Control, 3. Good health, 030220 oncology & carcinogenesis, Population, MESH : Europe, MEDLINE, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Epidemiologic Methods, 03 medical and health sciences, education, MESH: Humans, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, Data quality, MESH: Europe, MESH : Databases as Topic, business, computer, MESH: Databases as Topic, International Classification of Diseases for Oncology
Abstract: International audience; This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated. The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3.
Published: 2009
Full Text: View/download PDF

42. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses

Author: Paul Perrotte, Pierre I. Karakiewicz, Laurent Zini, Martine Jolivet-Tremblay, Claudio Jeldres, Arnauld Villers, Francesco Montorsi, Alain Duclos, Philippe Arjane, François Péloquin, Umberto Capitanio, Daniel Pharand, Jean Jacques Patard, Service d'urologie, Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Cancer Prognostics and Health Outcomes Unit, Department of urology, Università Vita-Salute San Raffaele, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], De Villemeur, Hervé, Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Zini, Laurent, Perrotte, Paul, Jeldres, Claudio, Capitanio, Umberto, Duclos, Alain, Jolivet Tremblay, Martine, Arjane, Philippe, Peloquin, Francoi, Pharand, Daniel, Villers, Arnauld, Montorsi, Francesco, Patard Jean, Jacque, and Karakiewicz Pierre, I.
Subjects: Nephrology, Male, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, medicine.medical_treatment, 030232 urology & nephrology, MESH: Epidemiologic Methods, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Nephrectomy, 0302 clinical medicine, Renal cell carcinoma, MESH: Risk Factors, Risk Factors, Cumulative incidence, MESH: Treatment Outcome, MESH: Aged, education.field_of_study, MESH: Middle Aged, MESH: Carcinoma, Renal Cell, Middle Aged, Prognosis, Kidney Neoplasms, 3. Good health, Treatment Outcome, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH: SEER Program, Female, medicine.medical_specialty, Urology, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Prognosis, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, MESH: United States, Humans, education, Carcinoma, Renal Cell, Survival analysis, Aged, MESH: Humans, business.industry, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Survival Analysis, MESH: Male, United States, Surgery, MESH: Nephrectomy, MESH: Kidney Neoplasms, business, Epidemiologic Methods, Kidney cancer, MESH: Female, Kidney disease, SEER Program
Abstract: OBJECTIVE To examine population-based rates of cancer-specific and other-cause mortality after either non-surgical management (NSM) or nephrectomy, in patients with small renal masses, as several reports from selected institutions support the applicability of surveillance in patients with small renal masses, but there are no population-based studies confirming the general applicability of this therapy. PATIENTS AND METHODS Of 43 143 patients with renal cell carcinoma identified in the 1988–2004 Surveillance, Epidemiology and End Results database, 10 291 had localized small renal masses (≤4 cm) and were offered NSM (433, 4.2%) or nephrectomy (9858, 95.8%). Univariable matched and multivariable unmatched competing-risks regression models were used in the analyses. RESULTS Cumulative incidence plots based on unmatched data, where the effect of other-cause mortality was controlled for, showed a 5.2%, 6.5% and 9.4% survival benefit for nephrectomy vs NSM at 1, 2 and 5 years after nephrectomy or diagnosis, respectively. The same magnitude of the benefit (4.5%, 5.6% and 8.0%) persisted in analyses matched for age, tumour size and year of diagnosis or of nephrectomy. Finally, in multivariable analyses, treatment type, age, tumour size and year of diagnosis or of nephrectomy were independent predictors. CONCLUSION Relative to nephrectomy, NSM appears to undermine the overall and cancer-specific survival of patients with small renal masses by as much as 9.4%, at 5 years.
Published: 2009
Full Text: View/download PDF

43. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

Author: Marin, Benoît, Thiébaut, Rodolphe, Bucher, Heiner, Rondeau, Virginie, Costagliola, Dominique, Dorrucci, Maria, Hamouda, Osamah, Prins, Maria, Walker, A. Sarah, Porter, Kholoud, Sabin, Caroline, Chêne, Geneviève, Mouillet, Evelyne, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Neuroépidémiologie Tropicale et Comparée (NETEC), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Basel Institute for Clinical Epidemiology, University Hospital Basel [Basel], Epidémiologie Clinique et Traitement de l'Infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Dipartimento di Malattie Infettive, Reparto di Epidemiologia, Istituto Superiore di Sanita [Rome], Department of Infectious Disease Epidemiology, Robert Koch Institute [Berlin] (RKI), Cluster Infectious Diseases, Amsterdam BioMed Cluster, Medical Research Council Clinical Trials Unit (MRC CTU), University College of London [London] (UCL), Research Department of Infection and Population Health [London], and CASCADE has been funded through grants from the European Union BMH4-CT97-2550, QLK2-2000-01431, QLRT-2001-01708 and LSHP-CT-2006-018949.
Subjects: MESH: Immune Tolerance, MESH: Liver Diseases, MESH: CD4 Lymphocyte Count, CD4 cell count, MESH: Epidemiologic Methods, MESH: Antiretroviral Therapy, Highly Active, Hepatitis, MESH: Neoplasms, Causes of death, highly active, MESH: Acquired Immunodeficiency Syndrome, MESH: Adolescent, MESH: Aged, MESH: Humans, MESH: Middle Aged, MESH: AIDS-Related Opportunistic Infections, MESH: Cardiovascular Diseases, MESH: Adult, Human Immunodeficiency Virus/AIDS, MESH: Male, Antiretroviral therapy, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Young Adult, Neoplasm, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Bacterial infection, MESH: Female
Abstract: International audience; OBJECTIVE: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). DESIGN: Observational multicentre cohorts. METHODS: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/microl. Outcomes were specific causes of death using a standardized classification. RESULTS: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/microl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58-69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18-44%), end-stage liver disease (33, 18-46%) and non-AIDS malignancies (34, 21-45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. CONCLUSION: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.
Published: 2009
Full Text: View/download PDF

44. Race affects access to nephrectomy but not survival in renal cell carcinoma

Author: Alain Duclos, Arnauld Villers, Philippe Arjane, Laurent Zini, Paul Perrotte, Umberto Capitanio, Jean Jacques Patard, Claudio Jeldres, Francesco Montorsi, Pierre I. Karakiewicz, De Villemeur, Hervé, Service d'urologie, Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Cancer Prognostics and Health Outcomes Unit, Department of urology, Università Vita-Salute San Raffaele, Département d'urologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Zini, Laurent, Perrotte, Paul, Capitanio, Umberto, Jeldres, Claudio, Duclos, Alain, Arjane, Philippe, Villers, Arnauld, Montorsi, Francesco, Patard Jean, Jacque, and Karakiewicz Pierre, I.
Subjects: Male, medicine.medical_treatment, 030232 urology & nephrology, Logistic regression, MESH: Epidemiologic Methods, Nephrectomy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Health Services Accessibility, 0302 clinical medicine, Renal cell carcinoma, 10. No inequality, MESH: Aged, MESH: Health Services Accessibility, MESH: Middle Aged, MESH: Carcinoma, Renal Cell, MESH: European Continental Ancestry Group, Middle Aged, Kidney Neoplasms, 3. Good health, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, MESH: SEER Program, Female, medicine.medical_specialty, Urology, Black People, [SDV.CAN]Life Sciences [q-bio]/Cancer, White People, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, Carcinoma, Renal Cell, Aged, MESH: Humans, Proportional hazards model, business.industry, medicine.disease, Comorbidity, Survival Analysis, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, Surgery, MESH: Nephrectomy, MESH: African Continental Ancestry Group, MESH: Kidney Neoplasms, business, Epidemiologic Methods, Kidney cancer, MESH: Female, Kidney disease, SEER Program
Abstract: International audience; OBJECTIVES: To assess whether, in contemporary patients with renal cell carcinoma (RCC), access to nephrectomy is the same between the Blacks and Whites, and that there is no difference in mortality after stratification for treatment type. PATIENTS AND METHODS: The effect of race has received little attention in RCC; only two reports have addressed and suggested the presence of racial disparities, including access to nephrectomy and survival after nephrectomy, where Black patients were disadvantaged relative to Whites. We used the Surveillance, Epidemiology and End Results data from 12 516 patients of all stages diagnosed and treated for RCC between 2000 and 2004. The effect of race (Black vs White) on nephrectomy rate was addressed in logistic regression and binomial regression models, and Cox regression models tested the effect of race on overall survival. RESULTS: Black patients were 50% less likely to have a nephrectomy than their White counterparts. However, race had no effect on overall survival when the entire cohort was assessed, as well as in subgroups of patients with or without nephrectomy. CONCLUSIONS: Although race is a determinant of access to nephrectomy, it should not be interpreted as a barrier to care, as survival was unaffected by race in patients having a nephrectomy or not. Instead, race might represent a proxy of comorbidity and life-expectancy, which represent surgical selection criteria for nephrectomy.
Published: 2009
Full Text: View/download PDF

45. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study

Author: Paul McCrone, Marc Verny, Gilles CHOPARD, Christoph Schrader, Jörg B. Schulz, Jan Kassubek, Nicholas Wood, Karen Elaine Morrison, Thomas Gasser, Martin Skalej, Beate Winner, Jürgen Winkler, David Burn, Arno Villringer, Richard Brown, K Ray Chaudhuri, Ammar Al-Chalabi, Georg Bernhard Landwehrmeyer, Claire Donnellan, Klaus Gröschel, Danielle Seilhean, Sue Evans, Immunologie - Immunopathologie - Immunothérapeutique (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institute of Psychiatry, Institute of psychiatry, Neuroépidémiologie Tropicale et Comparée (NETEC), Université de Limoges (UNILIM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Service de Neurologie [CHU Limoges], CHU Limoges, Service de Radiologie et Imagerie Médicale [CHU Limoges], Service de pharmacologie médicale [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Fédération des Maladies du Système Nerveux, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)
Subjects: Male, MESH: Multiple System Atrophy, multiple system atrophy, MESH: Epidemiologic Methods, Severity of Illness Index, law.invention, 0302 clinical medicine, MESH: Riluzole, Randomized controlled trial, law, Clinical endpoint, MESH: Treatment Outcome, MESH: Aged, 0303 health sciences, education.field_of_study, Riluzole, MESH: Middle Aged, MESH: Neuroprotective Agents, Middle Aged, Prognosis, 3. Good health, Neuroprotective Agents, Treatment Outcome, natural history, Disease Progression, Female, MESH: Disease Progression, Supranuclear Palsy, Progressive, MESH: Parkinson Disease, Secondary, medicine.drug, medicine.medical_specialty, Psychometrics, Population, Placebo, MESH: Prognosis, 03 medical and health sciences, MESH: Psychometrics, Internal medicine, MESH: Severity of Illness Index, Severity of illness, medicine, Humans, Parkinson Disease, Secondary, education, Aged, 030304 developmental biology, Intention-to-treat analysis, MESH: Humans, business.industry, Original Articles, progressive supranuclear palsy, eye diseases, MESH: Male, Surgery, Relative risk, randomized controlled trial, MESH: Supranuclear Palsy, Progressive, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Epidemiologic Methods, business, MESH: Female, 030217 neurology & neurosurgery
Abstract: International audience; Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-rigid syndrome diagnosed as having PSP or MSA according to modified consensus diagnostic criteria were considered for inclusion. The psychometric validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested prospectively by clinical and pathological assessments. The study was powered to detect a 40% decrease in relative risk of death within PSP or MSA strata. Patients were randomized to riluzole or matched placebo daily and followed up to 36 months. The primary endpoint was survival. Secondary efficacy outcomes were rates of disease progression assessed by functional measures. A total of 767 patients were randomized and 760 qualified for the Intent to Treat (ITT) analysis, stratified at entry as PSP (362 patients) or MSA (398 patients). Median follow-up was 1095 days (range 249-1095). During the study, 342 patients died and 112 brains were examined for pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent convergent validity with the investigators' assessment of diagnostic probability (point-biserial correlation: MSA r(pb) = 0.93, P < 0.0001; PSP, r(pb) = 0.95, P < 0.0001), and excellent predictive validity against histopathology [sensitivity and specificity (95% CI) for PSP 0.95 (0.88-0.98) and 0.84 (0.77-0.87); and for MSA 0.96 (0.88-0.99) and 0.91 (0.86-0.93)]. There was no evidence of a drug effect on survival in the PSP or MSA strata (3 year Kaplan-Meier estimates PSP-riluzole: 0.51, PSP-placebo: 0.50; MSA-riluzole: 0.53, MSA-placebo: 0.58; P = 0.66 and P = 0.48 by the log-rank test, respectively), or in the population as a whole (P = 0.42, by the stratified-log-rank test). Likewise, rate of progression was similar in both treatment groups. There were no unexpected adverse effects of riluzole, and no significant safety concerns. Riluzole did not have a significant effect on survival or rate of functional deterioration in PSP or MSA, although the study reached over 80% power to detect the hypothesized drug effect within strata. The NNIPPS diagnostic criteria were consistent and valid. They can be used to distinguish between PSP and MSA with high accuracy, and should facilitate research into these conditions relatively early in their evolution.
Published: 2009
Full Text: View/download PDF

46. Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma

Author: Jacques Tostain, Umberto Capitanio, Maxime Crepel, Laurent Zini, Jean Marie Ferriere, Francesco Montorsi, Jean-Christophe Bernhard, Arnauld Villers, Alexandre de la Taille, Christian Pfister, Vincenzo Ficarra, Pierre I. Karakiewicz, Jean Jacques Patard, Service d'urologie, Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Institut de Génétique et Développement de Rennes (IGDR), Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Department of urology, Università Vita-Salute San Raffaele, Service d'urologie-andrologie, CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] (UJM)-Hôpital nord, Department of Oncological and Surgical Sciences, Universita degli Studi di Padova, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Service d'Urologie - Andrologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Università degli Studi di Padova = University of Padua (Unipd), Zini, Laurent, Patard Jean, Jacque, Capitanio, Umberto, Crepel, Maxime, de La Taille, Alexandre, Tostain, Jacque, Ficarra, Vincenzo, Bernhard Jean, Christophe, Ferriere Jean, Marie, Pfister, Christian, Villers, Arnauld, Montorsi, Francesco, Karakiewicz Pierre, I., De Villemeur, Hervé, and CHU Saint-Etienne-Université Jean Monnet - Saint-Étienne (UJM)-Hôpital nord
Subjects: Male, Nephrology, medicine.medical_treatment, 030232 urology & nephrology, urologic and male genital diseases, MESH: Epidemiologic Methods, Nephrectomy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, prognostic factors, renal cell carcinoma, 0302 clinical medicine, Risk Factors, Renal cell carcinoma, MESH: Risk Factors, Medicine, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, Mortality rate, MESH: Carcinoma, Renal Cell, Middle Aged, Kidney Neoplasms, female genital diseases and pregnancy complications, 3. Good health, Europe, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Glomerular Filtration Rate, medicine.medical_specialty, Urology, Renal function, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, Carcinoma, Humans, Carcinoma, Renal Cell, Aged, MESH: Humans, business.industry, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, Surgery, MESH: Nephrectomy, MESH: Glomerular Filtration Rate, MESH: Europe, MESH: Kidney Neoplasms, Epidemiologic Methods, business, Kidney cancer, MESH: Female, Kidney disease
Abstract: OBJECTIVE To examine cancer-specific and non-cancer-related mortality rates in 451 patients with T1a–bN0M0 renal cell carcinoma (RCC) treated with either radical or partial nephrectomy (RN or PN) in Europe. PATIENTS AND METHODS Between 1987 and 2007, 451 patients with T1a–bN0M0 RCC were treated for histologically confirmed RCC with RN or PN at one of seven participating European institutions. The preoperative American Society of Anesthesiology (ASA) score was available for all patients and was used to control for baseline comorbidities. The preoperative glomerular filtration rate (GFR) was estimated using the Modification of Diet in Renal Disease study group equation. We used univariate and multivariate competing-risks regression analyses to test the effect of the ASA score, GFR, T stage (T1a vs T1b) and nephrectomy type (RN or PN) on RCC-specific mortality and non-RCC-related mortality. RESULTS In patients with T1a–b RCC cancer- specific mortality was unaffected by stage, nephrectomy type or GFR. Conversely, non-RCC-related mortality was strongly affected by the ASA score and GFR. Unlike in a previous report, nephrectomy type did not affect non-RCC-related mortality. This lack of significance relative to RN may stem from the relatively high rate of PN use in the present series. CONCLUSION PN or RN virtually eliminate the risk of cancer-specific mortality in patients with T1a–b RCC. Poor preoperative ASA score and impaired renal function appear to represent relative contra-indications to surgical management of T1a–b lesions.
Published: 2009
Full Text: View/download PDF

47. Neighbourhoods in eco-epidemiologic research: delimiting personal exposure areas. A response to Riva, Gauvin, Apparicio and Brodeur

Author: Juan Merlo, David J. Evans, Sabrina Havard, Basile Chaix, Cinira Leal, Chauvin, Pierre, ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unit for Social Epidemiology, Lund University [Lund], and École des Hautes Études en Santé Publique [EHESP] (EHESP)
Subjects: MESH: Social Environment, MESH: Urban Health, Health (social science), MESH: Ecological and Environmental Phenomena, MESH: Humans, MESH: Environment Design, MEDLINE, Social environment, Level design, MESH: Epidemiologic Methods, Geography, History and Philosophy of Science, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Environmental health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Epidemiologic research, MESH: Residence Characteristics, MESH: Models, Theoretical, ComputingMilieux_MISCELLANEOUS, Urban health
Abstract: International audience
Published: 2009
Full Text: View/download PDF

48. Bone mineral density at menopause does not predict breast cancer incidence

Author: Jean-Michel Pouilles, J. Laparra, C. Ribot, F. Tremollieres, Unité Ménopause et Maladies Osseuses Métaboliques, CHU Toulouse [Toulouse]-Hôpital Paule de Viguier, CHU Toulouse [Toulouse], Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Simon, Marie Francoise, Service Gynécologie [CHU Toulouse], Pôle Femme-Mère-Couple [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: MESH: Menopause, Endocrinology, Diabetes and Metabolism, Osteoporosis, MESH: Epidemiologic Methods, MESH: Lumbar Vertebrae, 0302 clinical medicine, Bone Density, Prospective cohort study, MESH: Bone Density, MESH: Femur Neck, Bone mineral, Lumbar Vertebrae, MESH: Middle Aged, Anthropometry, Obstetrics, Femur Neck, Estrogen Replacement Therapy, Age Factors, Middle Aged, Prognosis, Menopause, Postmenopause, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Menarche, Female, Breast disease, MESH: Postmenopause, medicine.medical_specialty, 030209 endocrinology & metabolism, Breast Neoplasms, MESH: Prognosis, 03 medical and health sciences, Breast cancer, MESH: Anthropometry, medicine, Humans, Femoral neck, Gynecology, MESH: Age Factors, MESH: Humans, business.industry, medicine.disease, MESH: Estrogen Replacement Therapy, Perimenopause, MESH: Perimenopause, business, Epidemiologic Methods, MESH: Female, MESH: Breast Neoplasms
Abstract: International audience; SUMMARY: In this prospective study in 2,137 perimenopausal and early postmenopausal women who were followed over a 13.1-year period of time, we observed no association between bone mineral density measured at the beginning of menopause and the subsequent risk of breast cancer. INTRODUCTION: This study aimed to investigate the relationship between BMD and the risk of breast cancer (BC) in young postmenopausal women. METHODS: As part of a clinical research program, 2,137 women who were perimenopausal or within their 5 first postmenopausal years were scanned between 1988-1990 and reviewed on average 13.1 years after their initial examination. Ninety-eight incident BC cases were recorded throughout the follow-up. RESULTS: Women with incident BC significantly differed from those who had never had BC with regard to age at menarche, age of birth of 1st child, familial history of BC and postmenopausal hormone therapy (PHT) use. There was no significant difference between the two groups for baseline DXA of the spine. There was a trend for BC cases for having lower femoral neck BMD compared to women without BC. However, women with low BMD were more likely to have taken PHT by the end of the study. In Cox multivariate analyses the relationship between BC risk and femoral neck BMD no longer existed. CONCLUSIONS: There was no relationship between BMD measured within the first postmenopausal years and the risk of BC, which makes unlikely the possibility of using BMD as a predictor factor for BC in early postmenopausal women.
Published: 2008
Full Text: View/download PDF

49. Screening for hip and knee osteoarthritis in the general population: predictive value of a questionnaire and prevalence estimates

Author: Roux, C. H., Saraux, Alain, Mazieres, B., Pouchot, J., Morvan, J., Fautrel, B., Testa, J., Fardellone, P., Rat, A. C., Coste, J., Guillemin, F., Euller-Ziegler, L., Renseigné, Non, Service de rhumatologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Centre de référence des syndromes drépanocytaires majeurs, Statistical Department (SD NICE), Centre Hospitalier Universitaire de Nice (CHU Nice), Service de Rhumatologie - AMIENS (AMIENS - Rhumato), CHU Amiens-Picardie, Centre d'Epidémiologie Clinique (CIC-EC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Statistical Department (SD COCHIN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des syndromes drépanocytaires majeurs-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), and Université de Lorraine (UL)
Subjects: Male, MESH: Range of Motion, Articular, [SDV]Life Sciences [q-bio], Prevalence, Osteoarthritis, MESH: Epidemiologic Methods, Osteoarthritis, Hip, 0302 clinical medicine, MESH: Osteoarthritis, Knee, Immunology and Allergy, Medicine, 030212 general & internal medicine, Range of Motion, Articular, MESH: Aged, education.field_of_study, MESH: Middle Aged, medicine.diagnostic_test, Middle Aged, Osteoarthritis, Knee, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Female, France, MESH: Pain, Range of motion, Adult, musculoskeletal diseases, medicine.medical_specialty, Immunology, Population, Pain, Physical examination, General Biochemistry, Genetics and Molecular Biology, MESH: Telephone, 03 medical and health sciences, MESH: Physical Examination, Age Distribution, Rheumatology, Internal medicine, Arthropathy, Humans, education, Physical Examination, MESH: Age Distribution, Aged, 030203 arthritis & rheumatology, MESH: Humans, business.industry, MESH: Adult, medicine.disease, Confidence interval, MESH: Male, Telephone, Radiography, MESH: France, Physical therapy, MESH: Osteoarthritis, Hip, Epidemiologic Methods, business, MESH: Female
Abstract: Objective: To study the feasibility and validity of a two-step telephone screening procedure for symptomatic knee and hip osteoarthritis (OA) in the general population. Method: The screening questionnaire was based on signs and symptoms, previous diagnosis of OA, and validated OA criteria. A random sample of telephone numbers was obtained and, at each number, one individual aged 40 to 75 years was included. A physical examination and knee or hip radiographs were offered when the screen was positive. A sample of individuals with negative screens was also examined. The diagnosis of hip/knee OA was based on the American College of Rheumatology criteria for signs and symptoms and Kellgren-Lawrence radiographic stage 2 or greater. Prevalence rates were estimated with correction for the performance of the screening procedure. Results: Of 1380 individuals, 479 had positive screens, among whom 109 were evaluated; Symptomatic radiographic OA was found in 50 individuals, at the knee (n=35) or hip (n=20). Corrected prevalence estimates of symptomatic OA were 7.6% [6.4-8.8] for the knee and 5% (3.9-6.1) for the hip. The screening procedure had 87% [95% confidence interval [95%CI], 79-95%] sensitivity, and 92% [95% CI: 91-93] specificity for detecting knee OA and respectively 93% [95% CI: 86-100] and 93% [95% CI: 92-94] for hip OA. Conclusion: This study establishes the feasibility of a telephone screening for symptomatic knee/hip OA, which could be used for a nationwide prevalence study. Pain and previous OA diagnosis were the best items for detecting symptomatic OA.
Published: 2008
Full Text: View/download PDF

50. Prevalence of hepatitis C infection and risk factors in hospitalized diabetic patients: results of a cross-sectional study

Author: Jean-Claude Barbare, Alexandre Pariente, Jean-Noël Barjon, Olivier Ribière, Patrice Dumouchel, Jean-Paul Bigué, Claude Eugène, Guy Lambrey, Gilles Duverlie, Jean-François Cadranel, Catherine Mourlhon, Marie-Laure Anciaux, Christian Richard, Vincent Di Martino, Dominique Capron, Bories C, Sandrine Jeanne, Arnaud Pauwels, Bruno Devergie, Sylvie Arlot, Bernard Nalet, Laurence Donato, Chantal Halimi, Service d'Hépato-Gastro-Entérologie, Hôpital Laennec, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Montélimar, CH Montélimar, Intensive Care Unit, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre hospitalier de Pau, Institut de biologie de Lille - IBL (IBLI), Université de Lille, Sciences et Technologies-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Cross-sectional study, Type 2 diabetes, MESH: Hospitalization, medicine.disease_cause, MESH: Epidemiologic Methods, 0302 clinical medicine, Epidemiology, 030212 general & internal medicine, Substance Abuse, Intravenous, MESH: Aged, Cross Infection, MESH: Middle Aged, Gastroenterology, Hepatitis C, Middle Aged, Hepatitis B, 3. Good health, Hospitalization, Female, 030211 gastroenterology & hepatology, France, Viral disease, Adult, medicine.medical_specialty, MESH: Diabetes Mellitus, Hepatitis C virus, MESH: Blood Transfusion, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Diabetes Mellitus, medicine, Humans, Risk factor, Aged, MESH: Humans, Hepatology, MESH: Hepatitis B, business.industry, Transfusion Reaction, MESH: Cross Infection, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hepatitis C Antibodies, medicine.disease, MESH: Male, MESH: France, MESH: Hepatitis C Antibodies, Immunology, MESH: Substance Abuse, Intravenous, Epidemiologic Methods, business, MESH: Female
Abstract: International audience; OBJECTIVES: Although there may exist a nosocomial risk of hepatitis C virus (HCV) infection in patients with type 1 or type 2 diabetes, this risk has not been fully investigated thus far and its magnitude is unknown. The aim of this multicenter cross-sectional study was to evaluate the prevalence of, and risk factors for, hepatitis C infection in consecutive hospitalized patients with diabetes and to assess the nosocomial risk and magnitude of HCV infection in these patients. PATIENTS AND METHODS: Consecutive hospitalized patients with diabetes seen in 11 French hepatogastroenterology and diabetology departments were studied. The prevalence of anti-HCV antibodies was compared with that observed in healthy blood donors and individuals seen during routine medical checkup. Diabetic patients with anti-HCV antibodies were compared with patients without anti-HCV antibodies for assessment of risk factors. RESULTS: In total 1561 patients were studied. Independent risk factors for HCV infection were assessed through multivariate analysis. Thirty-three patients (2.11%) had anti-HCV antibodies and 21 (63.70%) had HCV identified risk factors. The prevalence of HCV infection was higher in patients with diabetes than in blood donors (0.08%) or healthy controls (0.20%) (P2) of previous admissions since the onset of diabetes (OR=2.52, P=0.039). CONCLUSION: A nosocomial source of HCV infection in hospitalized diabetic patients is suggested by the increased risk of HCV infection associated with the number of hospitalizations. This may account for at least 36% of cases of HCV infection.
Published: 2008
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

80 results on '"MESH: Epidemiologic Methods"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources